Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same

ABSTRACT

Sulfoquinovosylacyl propanediol compounds represented by formula (I): 
     
       
         
         
             
             
         
       
     
     wherein R 1  is an acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and M represents a cation having a positive charge equal to Y and pharmaceutically acceptable salts thereof are effective for treating tumors.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional application of application Ser.No. 12/322,151, filed Jan. 29, 2009, which is a continuation applicationof International Application No. PCT/JP2008/063056, filed on Jul. 18,2008, and claims priority to Japanese Patent Application No.2007-190120, filed on Jul. 20, 2007, all of which applications areincorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to novel sulfonated sugar compounds andpharmaceutical compositions containing the same. The present inventionalso relates to novel methods of making such a compound and novelintermediates useful for making such a compound. The present inventionfurther relates to novel methods for treating a tumor by administeringsuch a compound.

2. Discussion of the Background

At present, in Japan, malignant tumors, cardiac disease, andcerebrovascular disease are responsible for about 60 percent of deaths.Among them, malignant tumor is the leading cause of death and isincreasing. For treating malignant tumors, the three major therapies aresurgical therapy, chemotherapy, and radiation therapy. In recent years,the quality of life (QOL) of a patient has been emphasized, and muchattention is being paid to radiation therapy.

In common radiation therapy, halogenated pyrimidine and hypoxic cellsensitizers are known as chemical or pharmaceutical substancesadministered simultaneously with radiation thereby enhancing itstherapeutic effect, more specifically, as clinically applicableradiosensitizers (for example, see Radiobiology for the Radiologist(Fourth Edition), Eric J. Hall et al, J. B. Lippincott Company(“Houshasennkainotameno Hoshasenseibutsugaku”, translated by MuneyasuUrano, Shinoharashinsha. Inc.). Examples of known halogenatedpyrimidines include 5-iododeoxyuridine. Examples of known hypoxic cellsensitizers include misonidazole. However, these known radiosensitizersare scarcely in actual use, because they produce side effects such asgastrointestinal disorders and peripheral neurotoxicity, and involveother outstanding problems.

On the other hand, novel radiosensitizers composed ofsulfopyranosylacylglycerol or salts thereof are disclosed in Jpn. Pat.Appln. No. 2004-374445. However, in sulfopyranosylacylglycerols, the2-position carbon atom in the glycerol moiety is an asymmetric carbon,so that the stereostructure cannot be controlled by a relativelyinexpensive and simple synthesis process as described in Jpn. Pat.Appln. No. 2004-374445, in which the terminal double bond of an allylgroup is dihydroxylated to form a glycerol skeleton. Therefore, R/Sdiastereomers are generated at a ratio of about 1:1. In order to solvethe problem, respective diastereomers can be independently synthesized,but such process requires bonding of a glycerol derivative having adefinite stereostructure to a sugar derivative during synthesis, whichresults in the complication of the synthesis process and an enormousincrease of the cost.

In addition, a sulfopyranosylacylglycerol derivative generates an R/Sdiastereoisomer (diastereomers) at the 2-position of the glycerolmoiety, as well as several percent of a structural isomer (2-acylisomer) Wherein the acyl group at the 1-position of glycerol has beentransferred to the 2-position between and/or within the molecules. These2-acyl isomers are generated during synthesis and storage in a solution.Therefore, even if the respective diastereomers are independentlyprepared, it is very difficult to provide a high puritysulfopyranosylacylglycerol derivative.

Although a sulfopyranosylacylglycerol derivative exhibits a noticeableradiosensitization effect, its development as a drug will entail verydifficult situations due to problems with synthesis and physicalproperties.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide anovel compounds which are useful for treating tumors.

It is another object of the present invention to provide novelpharmaceutical compositions which contain such a compound.

It is another object of the present invention to provide novel compoundswhich are useful as radiosensitizers.

It is another object of the present invention to provide novelpharmaceutical compositions which contain such a compound.

It is another object of the present invention to provide practicablenovel sulfonated sugar compounds and drugs or pharmaceuticalcompositions containing the same, and specifically to provide apracticable novel sulfonated sugar compounds obtainable at high purityby a simple synthesis method, and drug or pharmaceutical compositionscontaining the same.

It is another object of the present invention to provide novel methodsfor preparing such compounds.

It is another object of the present invention to provide novelintermediates which are useful for preparing such compounds.

It is another object of the present invention to provide novel methodsfor treating a tumor.

It is another object of the present invention to provide novel methodsof treating a tumor with radiation therapy.

As a result of dedicated research by the inventors, means for solvingthe above problems was found. Thus, the present invention provides:

(1) A sulfoquinovosylacyl propanediol compound represented by (I):

wherein R₁ is an acyl residue of a fatty acid, Y is a number of 1, 2 or3, and M represents a cation having a positive charge equal to Y,or pharmaceutically acceptable salt thereof.

(2) An anion represented by formula (I′):

wherein R₁ is an acyl residue of a fatty acid.

(3) A pharmaceutical composition, comprising at least onesulfoquinovosylacyl propanediol compound or pharmaceutically acceptablesalt thereof according to (1) and a pharmaceutically acceptable carrier.

(4) A pharmaceutical composition according to (3), which is aradiosensitizer.

(5) A pharmaceutical composition according to (3), which is anantineoplastic agent.

(6) A process for making a compound or pharmaceutically acceptable saltthereof according to (1), which comprises:

deprotecting a compound of formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isan acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and Mrepresents a cation having a positive charge equal to Y, to obtain saidcompound or pharmaceutically acceptable salt thereof according to (1).

(7) A process according to (6), wherein said compound of formula (IX) isprepared by a process comprising:

oxidizing a compound of formula (VIII):

wherein P¹, P², and P³ are each independently a protecting group, SAc isan acetylthio group, and R₁ is an acyl residue of a fatty acid, toobtain said compound of formula (IX).

(8) A process according to (7), wherein said compound of formula (VIII)is prepared by a process comprising:

reacting a compound of formula (VII):

wherein P¹, P², and P³ are each independently a protecting group, andSAc is an acetylthio group, with a compound of formula R₁C(═O)L, whereinR₁ is an acyl residue of a fatty acid and L is a leaving group, toobtain said compound of formula (VIII).

(9) A process according to (6), wherein said compound of formula (IX) isprepared by a process comprising:

reacting a compound of formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y, with a compound of formula R₁C(═O)L, wherein R₁ is an acylresidue of a fatty acid and L is a leaving group, to obtain saidcompound of formula (IX).

(10) A process according to (9), wherein said compound of formula (X′)is prepared by a process comprising:

-   -   converting a compound of formula (IX′):

wherein P¹, P², and P³ are each independently a protecting group, and Tsis a tosyl group, to said compound of formula (X′).

(11) A compound represented by formula (VIII):

wherein P¹, P², and P³ are each independently a protecting group, SAc isan acetylthio group, and R₁ is an acyl residue of a fatty acid.

(12) A compound represented by formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isan acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and Mrepresents a cation having a positive charge equal to Y.

(13) A compound represented by formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y.

(14) A compound represented by formula (IX′):

wherein P¹, P², and P³ are each independently a protecting group, and Tsis a tosyl group.

(15) A process for making a compound or pharmaceutically acceptable saltthereof according to (1), which comprises:

reacting a compound of formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents a cation having apositive charge equal to Y, with a compound of formula R₁C(═O)L, whereinR₁ is an acyl residue of a fatty acid and L is a leaving group, toobtain said compound or pharmaceutically acceptable salt thereofaccording to (1).

(16) A process according to (15), wherein said compound of formula (IX″)is prepared by a process comprising:

deprotecting a compound of formula (VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y, to obtain said compound of formula (IX″).

(17) A process according to (16), wherein said compound of formula(VIII″) is prepared by a process comprising:

oxidizing a compound of formula (VII):

wherein P¹, P², and P³ are each independently a protecting group and SAcis an acetylthio group, to obtain said compound of formula (VIII″).

(18) A compound represented by formula (VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y.

(19) A compound represented by formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents a cation having apositive charge equal to Y.

(20) A method of treating a tumor, comprising administering an effectiveamount of a compound according to (1) or a pharmaceutically acceptablesalt thereof to a subject in need thereof.

The present invention provides a practicable novel sulfonated sugarcompound and a drug including the same. Specifically, the presentinvention provides a novel sulfonated sugar compound obtainable at highpurity by a simple synthesis method, and a drug including the same.

A benefit of the present invention will be described in the followingdescription, and will be partially defined by the description or anembodiment of the present invention. A benefit of the present inventionwill be understood and achieved through drawings and below-describedcombinations.

BRIEF DESCRIPTION OF THE DRAWINGS

A more complete appreciation of the invention and many of the attendantadvantages thereof will be readily obtained as the same become betterunderstood by reference to the following detailed description whenconsidered in connection with the accompanying drawings, wherein:

FIG. 1 is a chromatogram showing the result of analysis of α SQAP C18:0.

FIG. 2 is a chromatogram showing the result of analysis of α SQMG C18:0.

FIG. 3 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 4 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 5 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 6 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 7 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 8 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 9 is a graph showing the effect of a test substance on the increaseof tumor volume.

FIG. 10 is a graph showing the effect of a test substance on the tubeformation.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

According to one aspect of the present invention, thesulfoquinovosylacyl propanediol compound expressed by formula (I) andpharmaceutically acceptable salts thereof are provided:

wherein R₁ is an acyl residue of a fatty acid, Y is a number of 1, 2 or3, and M represents a cation having a positive charge equal to Y.

In the present invention, when the “R₁” is an acyl residue of a fattyacid, the number of carbons contained therein is 26 or less and 1 ormore, and preferably 22 or less. The fatty acid for providing the acylresidue of a fatty acid according to the present invention may be alinear or branched, saturated or unsaturated fatty acid, and eachoccurrence of unsaturation may be in either the cis or trans or in the Zor E configuration.

Specific examples of R₁ include, but are limited to, methanoyl (formyl),ethanoyl (actyl), n-propoanoyl (n-propionyl), i-propoanoyl(i-propionyl), n-butanoyl, iso-butanoyl, sec-butanoyl, tert-butanoyl,n-pentanoly, iso-pentanoly, sec-pentanoyl, tert-pentanoyl,neo-pentanoyl, n-hexanoyl, iso-hexanolyl, sec-hexanoyl, tert-hexanoyl,neo-hexanoyl, n-heptanoyl, iso-heptanoyl, sec-heptanoyl, tert-heptanoyl,neo-heptanoyl, n-octanoyl, iso-octanoyl, sec-octanoyl, tert-octanoyl,neo-octanoyl, n-nonanoyl, iso-nonanoyl, sec-nonanoyl, tert-nonanoyl,neo-nonanoyl, n-decanoyl, iso-decanoyl, sec-decanoyl, tert-decanoyl,neo-decanoyl, n-undecanoyl, iso-undecanoyl, sec-undecanoyl,tert-undecanoyl, neo-undecanoyl, n-dodecanoyl, iso-dodecanoyl,sec-dodecanoyl, tert-dodecanoyl, neo-dodecanoyl, n-tridecanoyl,iso-tridecanoyl, sec-tridecanoyl, tert-tridecanoyl, neo-tridecanoyl,n-tertradecanoyl (myristoyl), iso-tertradecanoyl, sec-tertradecanoyl,tert-tertradecanoyl, neo-tertradecanoyl, n-pentadecanoyl,iso-pentadecanoyl, sec-pentadecanoyl, tert-pentadecanoyl,neo-pentadecanoyl, n-hexadecanoyl (palmitoyl), iso-hexadecanoyl,sec-hexadecanoyl, tert-hexadecanoyl, neo-hexadecanoyl, n-heptadecanoyl,iso-heptadecanoyl, sec-heptadecanoyl, tert-heptadecanoyl,neo-heptadecanoyl, n-octadecanoyl (stearoyl), iso-octadecanoyl,sec-octadecanoyl, tert-octadecanoyl, neo-octadecanoyl, n-nonadecanoyl,iso-nonadecanoyl, sec-nonadecanoyl, tert-nonadecanoyl, neo-nonadecanoyl,n-eicosanoyl, iso-eicosanoyl, sec-eicosanoyl, tert-eicosanoyl,neo-eicosanoyl, n-heneicosanoyl, iso-heneicosanoyl, sec-heneicosanoyl,tert-heneicosanoyl, neo-heneicosanoyl, n-docosanoyl, iso-docosanoyl,sec-docosanoyl, tert-docosanoyl, neo-docosanoyl, n-tricosanoyl,iso-tricosanoyl, sec-tricosanoyl, tert-tricosanoyl, neo-tricosanoyl,n-pentacosanoyl, iso-pentacosanoyl, sec-pentacosanoyl,tert-pentacosanoyl, neo-pentacosanoyl, n-hexacosanoyl, iso-hexacosanoyl,sec-hexacosanoyl, tert-hexacosanoyl, neo-hexacosanoyl, myristoleoyl,plamitoleoyl, oleoyl, linoleoyl, α-linoleoyl, arachidonoyl, euricoyl,and docosahexaenoyl. Of course, it is possible for the compound offormula (I) to exist as a mixture of compounds which contain two or moredifferent acyl groups for R₁.

The quinovose ring contained in the sulfoquinovosylacyl propanediolcompound according to the present invention may exist in a boat form, achair form, or a mixed conformation, but typically exists in a chairform because it is usually stable. The steric configuration of thepropanediol site in the quinovose ring may be an α anomer, a β anomer,or a mixture thereof.

The sulfoquinovosylacyl propanediol compound according to the presentinvention may be hereinafter referred to as “SQAP” or “SQAP compound”.In the term “α SQAP Cm:n”, “α” represents an α anomer, and “Cm:n”describes the group R₁, where the number of carbon atoms contained inthe R₁ group of SQAP is “m”, and the number of double bond(s) in the R₁group is “n”, wherein “m” is an integer of 1 or more, and “n” is aninteger of 0 or more. Accordingly, for example, “α SQAP C18:0”represents an α anomer of sulfoquinovosylacyl propanediol wherein thenumber of carbon atoms contained in the acyl residue of the fatty acidis 18, and the number of double bonds is 0.

Y is an integer which is 1, 2, or 3 and will depend on the positivecharge of the cation, M.

M may be any cation which has a charge of +1, +2 or +3. Preferred arepharmaceutically acceptable cations. Specific examples of suitablecations include, but are not limited to, proton (H⁺), lithium (Li⁺),sodium (Na⁺), potassium (K⁺), calcium (Ca⁺²), magnesium (Mg⁺²),manganese (Mn⁺² and Mn⁺³), iron (Fe⁺² and Fe⁺³), zinc (Zn⁺²), copper(Cu⁺¹, Cu⁺², and Cu⁺³), strontium (Sr⁺²), lead (Pb⁺²), silver (Ag⁺),barium (Ba⁺²), aluminum (Al⁺³), chromium (Cr⁺² and Cr⁺³), cobalt (Co⁺²and Co⁺³), nickel (Ni⁺² and Ni⁺³), ammonium, mono-, di-, tri-, andtetra-(C₁₋₄)-alkylammonium, and mono-, di-, tri-, andtetra-(C₁₋₄)-hydroxyalkylammonium.

The compound of formula (I) may also exist as a pharmaceuticallyacceptable salt, such as an acid addition salt or a salt in which one ofthe hydroxyl hydrogens is replaced by a cation.

In another embodiment, the present invention provides anions of theformula (I′):

wherein R₁ is the same acyl residue of a fatty acid as described inconnection with the compound of formula (I).

In another embodiment, the present invention provides intermediateswhich are useful for preparing the compounds of formula (I). One suchintermediate is represented by formula (VIII):

wherein P¹, P², and P³ are each independently a protecting group, SAc isan acetylthio group, and R₁ is the same acyl residue of a fatty acid asdescribed in connection with formula (I).

Another such intermediate is the compound represented by formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isthe same acyl residue of a fatty acid as described in connection withformula (I), Y is a number of 1, 2 or 3, and M represents the samecation as described in connection with formula (I).

Another intermediate is the compound represented by formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y.

Another such intermediate is the compound represented by formula (IX′):

wherein P¹, P², and P³ are each independently a protecting group, and Tsis a tosyl group.

Another such intermediate is the compound represented by formula(VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents the same cation as described inconnection with formula (I).

Another such intermediate is the compound represented by formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents the same cation asdescribed in connection with formula (I).

In the compounds of formulae (VIII), (IX), (X′), (IX′), and (VIII″), P¹,P², and P³ are each independently a protecting group. Any protectinggroup suitable for protecting a hydroxyl group may be used. Such groupsare described in Philip Kocienski, Protecting Groups, 3rd Edition, GeorgThieme Verlag, 2003; and Theodora W. Greene and Peter G. M. Wuts,Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & SonsInc., 1999, both of which are incorporated herein by reference.Particularly preferred protecting groups include benzyl groups,p-methoxybenzyl groups, 3,4-dimethoxybenzyl groups, 2,6-dimethoxybenzylgroups, p-phenylbenzyl groups, and 2-phenyl-2-propyl groups.

In another embodiment, the present invention provides methods forpreparing the compounds of formula (I). One such method involves:

A process for making a compound or pharmaceutically acceptable saltthereof according to (1), which comprises:

deprotecting a compound of formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isthe same acyl residue of a fatty acid as described in connection withthe compound of formula (I), Y is a number of 1, 2 or 3, and Mrepresents the same cation as described in connection with formula (I),to obtain said compound or pharmaceutically acceptable salt thereofaccording to (1).

The deprotection of the compound of formula (IX) may be achieved by anysuitable means, depending on the exact identity of the protectinggroups. See, Philip Kocienski, Protecting Groups, 3rd Edition, GeorgThieme Verlag, 2003; and Theodora W. Greene and Peter G. M. Wuts,Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & SonsInc., 1999, both of which are incorporated herein by reference. When theprotecting groups are benzyl groups, good results are achieved bycatalytic hydrogenation, using a catalyst such as platinum, rhodium,ruthenium, palladium activated carbon, Raney nickel, etc.

In one preferred embodiment, the compound of formula (IX) is prepared bya process comprising:

oxidizing a compound of formula (VIII):

wherein P¹, P²; and P³ are defined above, SAc is an acetylthio group,and R₁ is the same acyl residue of a fatty acid as described inconnection with the compound of formula (IX).

The oxidation of the compound of formula (VIII) may be carried out withany suitable oxidizing agent. Examples of suitable oxidizing agentsinclude, but are not limited to, OXONE® (2 KHSO₅.KHSO₄.K₂SO₄),H₂O₂.HCOOH, H₂O₂.CH₃COOH, H₂O₂.CF₃COOH, H₂O₂.H₂O and dimethyldioxirane.Particularly good results have been achieved by using potassiumperoxymonosulfate, KHSO₅, such as Oxone®, which is commerciallyavailable from DuPont. The oxidation may be carried out in any suitablesolvent and under time and temperature conditions suitable for obtainingthe compound of formula (IX).

In another preferred embodiment, the compound of formula (VIII) isprepared by a process comprising:

reacting a compound of formula (VII):

wherein P¹, P², P³, and SAc are as defined above,

with a compound of formula R₁C(═O)L, wherein R₁ is the same acyl residueof a fatty acid as described in connection with the compound of formula(I), and L is a leaving group.

In the compound of formula R₁C(═O)L, L may be any leaving group, whichis suitable for reacting with the hydroxyl group in the compound offormula (VII) to form the compound of formula (VIII). Suitable examplesinclude, but are not limited to, fluoride, chloride, bromide, andiodide. In addition, L may be a group of the formula R₁C(═O)—, such thatthe compound of formula R₁C(═O)L is an acid anhydride. Further, L may bean alcohol moiety, such that the compound of formula R₁C(═O)L is anactive ester, such as an N-hydroxyphthalimide ester or a2,4,6-trimethylbenzyl ester.

The reaction of the compound of formula (VII) with the compound offormula R₁C(═O)L, may be carried out in any suitable solvent, such asdichloromethane, chloroform, benzene, toluene, etc. This step may alsobe carried out in the presence of a base, such pyridine, etc. The molarratio of the compound of formula (VII) to the compound of formulaR₁C(═O)L may be approximately 1:1 or the compound of formula R₁C(═O)Lmay be used in a slight excess. The reaction time and temperature may besuitably adjusted to achieve the desired compound in good amount in aconvenient time.

In another preferred embodiment, the compound of formula (IX) isprepared by a process comprising:

reacting a compound of formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y, with a compound of formula R₁C(═O)L, wherein R₁ is an acylresidue of a fatty acid and L is a leaving group.

The reaction of the compound of formula (X′) with the compound offormula R₁C(═O)L, may be carried out in substantially the same way asthe reaction of the compound of formula (VII) with the compound offormula R₁C(═O)L. Thus, this reaction may be carried out in any suitablesolvent, and molar ratio of reactants, the reaction time and temperaturemay be suitably adjusted to achieve the desired compound in good amountin a convenient time. In this particularly good results have beenachieved by reacting the compound of formula (X′) with a fatty acid offormula R₁C(═O)OH in a solvent of N,N-dimethylformamide and in thepresence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloridand 4-dimethylaminopyridine.

In another preferred embodiment, the compound of formula (X′) isprepared by a process comprising:

converting a compound of formula (IX′):

wherein P¹, P², and P³ are defined above and Ts is a tosyl group, tosaid compound of formula (X′).

The conversion of the compound of formula (IX′) to the compound offormula (X′) may be carried out with any suitable reagent, such assodium sulfite, and in any suitable solvent, such as ethanol, water, andmixtures thereof.

In another embodiment, the compounds and pharmaceutically acceptablesalts of formula (I) may be prepared by a process involving:

reacting a compound of formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents a cation having apositive charge equal to Y, with a compound of formula R₁C(═O)L, whereinR₁ is an acyl residue of a fatty acid and L is a leaving group.

In this case, the leaving groups may be the same as described above, andthe reaction of the compound of formula (IX″) with the compound offormula R₁C(═O) L may be carried out in substantially the same way asthe reaction of the compound of formula (X′) with the compound offormula R₁C(═O)L.

In another preferred embodiment, the compound of formula (IX″) isprepared by a process comprising:

deprotecting a compound of formula (VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y. In this case, the protecting groups may be the same asdescribed above, and the deprotection of the compound of formula (VIII″)may be carried in substantially the same way as the deprotection stepsdescribed above.

In another preferred embodiment, the compound of formula (VIII″) isprepared by a process comprising:

oxidizing a compound of formula (VII):

wherein P¹, P², and P³ are defined above and SAc is an acetylthio group.

In this case, the oxidation of the compound of formula (VII) may becarried out substantially as described above for compound (VIII).

The method for preparing the sulfoquinovosylacyl propanediol compoundaccording to the present invention may be, but is not limited to, thefollowing detailed methods described below. Since thesulfoquinovosylacyl propanediol compound according to the presentinvention will not generate new asymmetric carbon during the synthesisprocess, the compound can be prepared easily, simply, and at highpurity. In addition, the compound can be stored in a structurally stablestate, because there is no hydroxy group, which readily causes transfer,present near the R₁ group.

In the following scheme, “Ph” represents a phenyl group, “Bn” representsa benzyl group, “Ts” represents a tosyl group, “SAc” represents anacetylthio group, and “M” represents a hydrogen ion or a metal ion.

In the scheme shown above, the steps A through I involve:

A) A-1. allyl alcohol, trifluoromethanesulfonic acid, 80° C., 48 hours;

A-2. benzaldehyde dimethyl acetal, p-toluenesulfonic acid monohydrate,acetonitrile, 40° C., 4 hours;

B) benzyl bromide, sodium hydroxide, N,N-dimethylformamide, roomtemperature, 24 hours;

C) lithium hydride aluminum, aluminum chloride, dichioromethane, diethylether, heating under reflux, 4 hours;

D) p-toluenesulfonyl chloride, 4-dimethylaminopyridine, pyridine, roomtemperature;

E) 9-borabicyclononane, tetrahydrofuran, room temperature, 10 hours;water, sodium hydroxide, hydrogen peroxide water, room temperature, 12hours;

F) potassium thioacetate, N,N-dimethylformamide, 90° C., 3 hours;

G) fatty acid derivative, pyridine, dichloromethane, room temperature, 2hours;

H) Oxone®, acetic acid, potassium acetate, room temperature, 48 hours;and

I) palladium activated carbon, hydrogen gas, ethanol, dichloromethane,room temperature, 48 hours.

Alternatively, after the compound (7) is prepared via the routeincluding the steps A to F, the intended compound (10) may be obtainedvia the following steps:

J) Oxone®, acetic acid, potassium acetate, room temperature, 48 hours;

K) palladium activated carbon, hydrogen gas, methanol, dichloromethane,room temperature, 16 hours; and

L) fatty acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride, 4-dimethylaminopyridine, N,N-dimethylformamide, from 0°C. to room temperature, 18 hours.

The method for preparing the sulfoquinovosylacyl propanediol compoundaccording to the present invention is not limited to the above-givenspecific example, and the following additional detailed method may beused instead.

In the next scheme, “Ac” represents an acetyl group, “MP” represents ap-methoxyphenyl group, “PMB” represents a p-methoxybenzyl group, “Ts”represents a tosyl group, and “M” represents a hydrogen ion or a metalion.

In the scheme shown above, the steps A′ through K′ involve:

A′) acetic anhydride, sodium acetate, heating and boiling;

B′) hydrobromic acid-acetic acid solution, dichloromethane, roomtemperature, 6 hours;

C′) allyl alcohol, cyanide mercury, dichloromethane, room temperature,16 hours;

D′) D′-1.sodium methoxide, methanol, room temperature, 4 hours;

D′-2. p-anisaldehyde dimethyl acetal, p-toluenesulfonic acidmonohydrate, acetonitrile, 40° C., .16 hours;

E′) p-methoxybenzyl chloride, sodium hydroxide, N,N-dimethylfortnamide,room temperature, 16 hours;

F′) lithium hydride aluminum, aluminum chloride, dichloromethane,diethyl ether, 0° C., 1 hour;

G′) p-toluenesulfonyl chloride, 4-dimethylaminopyridine, pyridine, roomtemperature, 16 hours;

H′) 9-borabicyclo nonane, tetrahydrofuran, room temperature, 16 hours;water, sodium hydroxide, hydrogen peroxide water, room temperature, 4hours;

I′) sodium sulfite, ethanol, water, heating under reflux, 72 hours;

J′) fatty acid derivative, 4-dimethylaminopyridine, pyridine,dichloromethane, heating under reflux, 16 hours; and

K′) 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, dichloromethane,methanol, water, room temperature, 4 hours.

Alternatively, any procedures known to those skilled in the art may becombined thereby preparing the sulfoquinovosylacyl propanediol compoundand pharmaceutically acceptable salts thereof according to an aspect ofthe present invention. These preparation methods are also included inthe scope of the present invention.

Examples of the sulfoquinovosylacyl propanediol compound expressed bythe general formula (I) and pharmaceutically acceptable salts thereofaccording to the present invention include, but are not limited to,salts of monovalent cations such as sodium and potassium, and salts ofdivalent cations such as calcium and magnesium.

The salts according to the present invention may be prepared by theabove-described synthesis method, or a modification of the synthesismethod. Alternatively, the product synthesized by the above-describedmethod may be subjected to a known ion exchange treatment to obtain thedesired salt. These methods for synthesizing the salts according to thepresent invention are also included within the scope of the presentinvention.

The sulfoquinovosylacyl propanediol compound and pharmaceuticallyacceptable salts thereof according to the present invention have notablepharmacological effects such as radiation sensitizing effects andantineoplastic effects.

Therefore, according to another aspect of the present invention, thesulfoquinovosylacyl propanediol compound and pharmaceutically acceptablesalts thereof may be provided as drugs utilizing their pharmacologicaleffects.

Thus, according to another aspect of the present invention, thesulfoquinovosylacyl propanediol compound and pharmaceutically acceptablesalts thereof have sensitizing effects as a first pharmacologicaleffect. Accordingly, the sulfoquinovosylacyl propanediol compound andpharmaceutically acceptable salts thereof may be provided asradiosensitizers.

The radiosensitizer according to the present invention may be used fortreating malignant neoplasm. Examples of malignant neoplasm include, butare not limited to, neurogenic tumors such as cerebral tumor; squamouscell carcinoma and adenocarcinoma, such as head and neck cancer, skincancer, esophagus cancer, thyroid cancer, stomach cancer, lung cancer,gallbladder cancer, biliary tract cancer, pancreas cancer, liver cancer,prostate cancer, uterus cancer, ovarian cancer, breast cancer, kidneycancer, bladder cancer, and colon cancer; and melanoma, osteoma, softtissue tumors, and lymphoma, leukemia, and myeloma. The term “treatment”used herein refers to the reduction, destruction, and/or inhibition ofenhancement (growth) of the above-described malignant neoplasm.

The radiosensitizer according to the present invention may contain, asan active ingredient, an effective dose of at least one compoundselected from the group consisting of the sulfoquinovosylacylpropanediol compounds expressed by the general formula (I) andpharmaceutically acceptable salts thereof. The radiosensitizer maycontain more than one kind of compounds having different substituents R₁in the general formula (I). In addition, the radiosensitizer may becombined with other radiosensitizer(s), an antitumor agent(s), or othersubstance having pharmacological activity and/or pharmaceutical activitywithout affecting its activity.

Hereinafter, the compounds consisting of the sulfoquinovosylacylpropanediol compound expressed by the general formula (I) andpharmaceutically acceptable salts thereof according to the presentinvention may be referred to as “radiosensitizing substance of thepresent invention”.

The radiosensitizing substance of the present invention may be given by,for example, oral administration or parenteral administration. Accordingto these administration routes, the radiosensitizing substance of thepresent invention may be combined with an appropriate pharmaceuticallyacceptable drug additive such as an excipient or diluent thereby makinga pharmaceutical preparation. The radiosensitizer according to thepresent invention shall contain an effective dose of theradiosensitizing substance of the present invention, and may be providedas a pharmaceutical preparation as described above.

Examples of dosage forms suitable for oral administration include solid,semi-solid, liquid, and gas forms, and specific examples of thereofinclude, but are not limited to, tablets, capsules, powders, granules,solutions, suspending agents, syrups, elixirs, and aerosols.

When the radiosensitizing substance of the present invention isparenterally administered, it may be given by, for example, injection,transdermal administration, rectal administration, or ocularadministration.

Administration by injection may be conducted through, for example,hypodermic, intradermal, intravenous, or intramuscular injection.

The conditions for administering the radiosensitizing substance of thepresent invention (for example, dose, frequency of administration, andinterval of administration) may be appropriately established andadjusted according to the dosage form, administration route, disease tobe treated, for example, state of malignant neoplasm (for example, type,location, and stage), conditions such as the drug to be combined (forexample, presence or absence of combined drug, type, dose, frequency,and timing of administration of combined drug, and sequence ofadministration of the combined drug and the radiosensitizing substanceof the present invention), the manner of combination with radiation (forexample, the timing of combination and the order of the administrationof the radiosensitizing substance of the present invention), and theconditions of the subject to be treated (for example, body weight, sex,and age).

For example, the dose of the radiosensitizing substance may be, but isnot limited to, from 0.001 to 100 mg/kg body weight per day via oraladministration, 0.001 to 50 mg/kg body weight per day via injection,from 0.001 to 100 mg/kg body weight per day via transdermaladministration, 0.001 to 50 mg/kg body weight per day via rectaladministration, or instillation of an about 0.001 to 3 wt. % solutionseveral times a day via ocular administration.

In the radiotherapy treatment, the type, dose, and frequency ofradiation may follow the conditions for conventional radiotherapytreatment. Specifically, conventional radiotherapy treatment for humanis conducted through, for example, exposure to medical radiation such asan X ray, γ ray, electron ray, β ray, or other particle beams such asπ-meson, neutron, or heavy particle beams with an irradiation dose ofabout 0.1 to 100 Gy per time over a period of one week to 6 months togive a total irradiation dose of about 10 to 500 Gy. Typical example ofhuman radiotherapy is conducted by, not limited to, X ray irradiationwith a dose of 2 Gy per time for five times thereby giving a total doseof 60 Gy over a period of about 6 weeks. For example, the dose andfrequency of irradiation may be reduced. Other examples of theradiotherapy method include conformation radiotherapy, stereotacticirradiation wherein the focus of malignant neoplasm is shot withpinpoint precision, or intensity modulated radiotherapy. In addition,irradiation with encapsulated sealed radioactive source, γ rayteletherapy, or irradiation with particle beams also may be used. Theirradiation dose per time may be increased, and the irradiation periodmay be reduced through internal irradiation.

Radiation therapy and administration of the radiosensitizer of thepresent invention may be conducted concurrently or sequentially. In thiscase, the radiosensitizer of the present invention is expected to serveas an antineoplastic agent to be combined with radiation therapy.Accordingly, according to another aspect of the present invention, thenovel sulfoquinovosylacyl propanediol compound or pharmaceuticallyacceptable salts thereof according to the present invention may beprovided as an antineoplastic agent to be combined with radiationtherapy.

As known to those skilled in the field of radiotherapy treatment, theconditions of radiation therapy and administration of theradiosensitizer of the present invention may be appropriately selectedby health professionals or other specialists depending on, for example:the type of radiation source, irradiation method, site and period ofirradiation; type of sensitizer, route and timing of administration;type and seriousness of the disease to be treated; and age, body weight,health condition, and medical history of the subject to be exposed toradiation.

In addition, according to yet another aspect of the present invention,provided is a therapy for treating a disease against which radiationtherapy is effective, including administration of an effective dose ofthe radiosensitizing substance to the subject in need of the substance.The term “a disease against which radiation therapy is effective” refersto a disease which is effectively treated by, for example, radiationtherapy on the above-described malignant neoplasm. Details about theradiosensitizing substance and method and conditions of itsadministration may be as described above.

The therapy according to the present invention may includeadministration of an effective dose of the radiosensitizing substance tothe subject in need of the substance, concurrently with radiationtherapy, or before or after the radiation therapy.

According to yet another aspect of the present invention, thesulfoquinovosylacyl propanediol compound and pharmaceutically acceptablesalts thereof have antineoplastic effect as a second pharmacologicaleffect. More specifically, they synergistically accelerate the radiationeffect, and can suppress malignant neoplasm when used alone.Accordingly, the sulfoquinovosylacyl propanediol compound andpharmaceutically acceptable salts thereof may be provided as anantineoplastic agent.

When the sulfoquinovosylacyl propanediol compound and pharmaceuticallyacceptable salts thereof are used as an antineoplastic agent, forexample, they may be used in the same manner as the above-describedradiosensitizer, except that they are not combined with radiationtherapy.

In this case, the conditions for administering the sulfoquinovosylacylpropanediol compound (for example, dose, frequency of administration,and interval of administration) may be appropriately established andadjusted according to the dosage form, administration route, disease tobe treated, for example, state of malignant neoplasm (for example, type,location, and stage), conditions such as the drug to be combined (forexample, presence or absence of combined drug, type, dose, frequency,and timing of administration of combined drug, and sequence ofadministration of the combined drug and the radiosensitizing substanceof the present invention), and the conditions of the subject to betreated (for example, body weight, sex, and age).

The various methods of treatment of the present invention may be appliedto any subject in need thereof. Suitable subjects include but are notlimited to mammals such as humans, chimpanzees, gorillas, monkeys,baboons, orangutans, dogs, cats, horses, cows, pigs, oxen, llamas,alpacas, bison, buffalo, camels, zebras, elephants, giraffes,hippopotami, bears, lions, tigers, leopards, antelope, etc. In apreferred embodiment the subject is a human.

Other features of the invention will become apparent in the course ofthe following descriptions of exemplary embodiments which are given forillustration of the invention and are not intended to be limitingthereof.

EXAMPLES Example I

The steps for preparing the sulfoquinovosylacyl propanediol compoundaccording to the present invention are described below taking, as anexample, a sodium salt of α-sulfoquinovosyl stearoyl propanediol.

A) A-1. allyl alcohol, trifluoromethanesulfonic acid, 80° C., 48 hours;

A-2. benzaldehyde dimethyl acetal, p-toluene sulfonic acid monohydrate,acetonitrile, 40° C., 4 hours,

B) benzyi bromide, sodium hydroxide, N,N-dimethylformamide, roomtemperature, 24 hours, 84.4%;

C) lithium hydride aluminum, aluminum chloride, dichloromethane, diethylether, heating under reflux, 4 hours, 90.2%;

D) p-toluenesulfonyl chloride, 4-dimethylaminopyridine, pyridine, roomtemperature, 16 hours, 87.9%;

E) 9-borabicyclononane, tetrahydrofuran, room temperature, 10 hours;water, sodium hydroxide, hydrogen peroxide water, room temperature, 12hours, 94.4%;

F) potassium thioacetate, N,N-dimethylforrnamide, 90° C., 3 hours,90.8%;

G) stearoyl chloride, pyridine, dichloromethane, room temperature, 2hours, 97.4%;

H) Oxone®, acetic adid, potassium acetate, room temperature, 48 hours,88.6%; and

I) palladium activated carbon, hydrogen gas, ethanol, dichloromethane,room temperature, 48 hours, 79.4%.

The procedure for obtaining, as the end product, a sodium salt ofα-sulfoquinovosyl stearoyl propanediol according to an aspect of thepresent invention was conducted via the steps A to I in theabove-described scheme.

Example I-1 Step A: 1-O-allyl-4,6-O-benzylidene-α-D-glucopyranose (2)

The compound (1) (100 g, 555 mmol) as the starting substance wassuspended in allyl alcohol (500 ml), to which trifluoromethanesulfonicacid (1.00 ml) was added at 0° C., and the reaction liquid wasvigorously stirred at 80° C. for 48 hours. After the sufficient progressof the reaction was confirmed, triethylamine (3 ml) was added to stopthe reaction, and the reaction liquid was concentrated under reducedpressure. Subsequently, the residue was suspended in anhydrousacetonitrile (500 ml), to which benzaldehyde dimethyl acetal (127 g, 1.5equivalent) and p-toluenesulfonic acid monohydrate (5.28 g, 0.05equivalent) were added. The reaction liquid was stirred at, 40° C. for 4hours, to which triethylamine (10 ml) was added to stop the reaction,and the reaction liquid was concentrated under reduced pressure. Theresidue was poured to hexane (2000 ml) and water (500 ml), and the mixedliquid was vigorously stirred. The generated precipitate was collectedby filtration, and rinsed with water and hexane. The precipitate wascrystallized from heated ethanol twice to obtain the title compound (2)in the form of colorless needle crystals {34.5 g (112 mmol), 20.2%}.[α]²³ _(D) +97.5° (c1.00 CH₃OH), LRMS m/z 331 (M+Na)⁺, mp 139-141° C.

¹H NMR (400 MHz, CD₃OD); δ 7.51-7.47 (m, 2H, ArH), 7.37-7.32 (m, 3H,ArH), 5.99 (dddd, 1H, J=17.2, 10.5, 6.08, 5.32 Hz, H2), 5.56 (s, 1H,PhCH), 5.36 (dq, 1H, J=17.3, 1.68 Hz, H3a), 5.20 (ddt, 1H, J=10.4, 1.80,1.28 Hz, H3b), 4.88 (d, 1H, J=3.86 Hz, H1′), 4.25-4.18 (m, 2H, H1a &H6′a), 4.07 (ddt, 1H, J=13.0, 6.10, 1.36 Hz, H1b), 3.85 (t, 1H, J=9.38Hz, H3′), 3.81-3.71 (m, 2H, H5′ & H6′b), 3.52 (dd, 1H, J=9.38, 3.86 Hz,H2′), 3.45 (t, 1H, J=9.24 Hz, H4′).

¹³C NMR (100 MHz, CD₃OD); δ 139.1 (Ar-ipso), 135.4 (C2), 129.9 (Ar),129.0 (Ar), 127.5 (Ar), 117.8 (C3), 103.0 (PhCH), 100.0 (C1′), 82.9(C4′), 74.0 (C2′), 72.0 (C3′), 69.9 (C6′), 69.7 (C1), 64.1 (C5).

Example I-2 Step B;1-O-allyl-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranose (3)

To a solution of the compound (2) (30.0 g, 97.3 mmol) in anhydrousN,N-dimethylformamide (DMF, 300 ml) were added benzyl bromide (41.6 g,2.5 equivalents) and sodium hydroxide (11.7 g, 3.0 equivalents), and thereaction liquid was vigorously stirred at room temperature for 24 hours.After the sufficient progress of the reaction was confirmed, thereaction liquid was poured to chilled water (900 ml), and extracted withethyl acetate (3×300 ml). The organic layers were combined and washedwith saturated saline (2×100 ml), dried with sodium sulfate, filtered,concentrated under reduced pressure. The obtained residue wascrystallized twice from heated ethanol to obtain the title compound (3)in the form of colorless needle crystals (33.5 g). The filtrate wasconcentrated, purified with silica gel chromatography (hexane-ethylacetate, 15:1→10:1→8:1), crystallized from heated ethanol to obtain thecompound (3) (6.63 g) {40.1 g (82.1 mmol) in total, 84.4%}.

[α]²⁶ _(D) −1.46° (c1.03 CHCl₃), LRMS m/z 511 (M+Na)⁺, mp 86-87° C.

¹H NMR (400 MHz, CDCl₃); δ 7.50-7.47 (m, 2H, ArH), 7.40-7.24 (m, 13H,ArH), 5.94 (dddd, 1H, J=17.0, 10.4, 6.70, 5.24 Hz, H2), 5.56 (s, 1H,PhCH), 5.33 (dq, 1H, J=17.2, 1.56 Hz, H3a), 5.24 (ddt, 1H, J=10.3, 1.56,1.12 Hz, H3b), 4.92 (d, 1H, J=11.2 Hz, ArCH₂), 4.84 (d, 1H, J=11.2 Hz,ArCH₂), 4.83 (d, 1H, J=12.1 Hz, ArCH₂), 4.80 (d, 1H, J=3.76 Hz, H1′),4.68 (d, 1H, J=12.1 Hz, ArCH₂), 4.26 (dd, 1H, J=10.2, 4.84 Hz, H6′a),4.18 (ddt, 1H, J=12.9, 5.18, 1.40 Hz, H1a), 4.79 (t, 1H, J=9.30 Hz,H3′), 4.03 (ddt, 1H, J=12.9, 6.68, 1.20 Hz, H1b), 3.89 (dt, 1H, J=9.96,4.80 Hz, H5′), 3.70 (t, 1H, J=10.3 Hz, H6′b), 3.61 (t, 1H, J=9.44 Hz,H4′), 3.57 (dd, 1H, J=8.72, 3.80 Hz, H2′).

¹³C NMR (100 MHz, CDCl₃); δ 138.7 (Ar-ipso), 138.1 (Ar-ipso), 137.3(Ar-ipso), 133.5 (C2), 128.9-127.5 (m, Ar), 126.0 (Ar), 118.4 (C3),101.2 (PhCH), 96.7 (C1′), 82.1 (C3′), 79.1 (C2′), 78.6 (C4′), 75.3(ArCH₂), 73.6 (ArCH₂), 69.0 (C6′), 68.4 (C1), 62.5 (C5′).

Example I-3 Step C; 1-O-allyl-2,3,4-tri-O-benzyl-α-D-glucopyranose (4)

Aluminum lithium hydride (2.02 g, 1.3 equivalents) is suspended in amixed solution of anhydrous dichloromethane (100 ml) and anhydrousdiethyl ether (100 ml), to which the compound 3 (20.0 g, 40.9 mmol) wasadded. Subsequently, to the reaction liquid, added was 200 ml of analuminum chloride (7.09 g, 1.3 equivalents) solution in anhydrousdiethyl ether, and the mixture was stirred for 4 hours under heating andreflux. After the sufficient progress of the reaction was confirmed,water (10 ml) was slowly added dropwise, the precipitate was collectedby filtration after standing overnight, and then the precipitate wasrinsed with diethyl ether. The filtrate was washed with water (2×100ml), the aqueous layers were combined, and extracted with diethyl ether(2×100 ml). The organic layers were combined and washed with saturatedsaline (2×200 ml), dried with sodium sulfate, filtered, and concentratedunder reduced pressure. The obtained residue was purified with silicagel chromatography (hexane-ethyl acetate, 5:1→4:1→3:1→2:1) to obtain thetitle compound 3 in the form of a colorless oily substance {18.1 g (36.9mmol), 90.2%}.

[α]²² _(D) +45.0° (c1.21 CHCl₃), LRMS m/z 513 (M+Na)⁺.

¹H NMR (400 MHz, CDCl₃); δ 7.37-7.26 (m, 15H, ArH), 5.92 (dddd, 1H,J=17.1, 10.4, 6.66, 5.24 Hz, H2), 5.31 (dq, 1H, J=17.2, 1.52 Hz, H3a),5.22 (ddt, 1H, J=10.3, 1.46, 1.10 Hz, H3b), 5.00 (d, 1H, J=10.9 Hz,ArCH₂), 4.89 (d, 1H, J=11.0 Hz, ArCH₂), 4.84 (d, 1H, J=10.9 Hz, ArCH₂),4.77 (d, 1H, J=12.0 Hz, ArCH₂), 4.77 (d, 1H, J=3.60 Hz, H1′), 4.65 (d,1H, J=12.1 Hz, ArCH₂), 4.64 (d, 1H, J=11.0 Hz, ArCH₂), 4.14 (ddt, 1H,J=12.9, 5.22, 1.34 Hz, H1a), 4.04 (t, 1H, J=9.36 Hz, H3′), 3.99 (ddt,1H, J=12.9, 6.64, 1.08 Hz, H1b), 3.79-3.66 (m, 3H, H5′ & H6′a & H6′b),3.54 (t, 1H, J=9.28 Hz, H4′), 3.51 (dd, 1H, J=9.60, 3.64 Hz, H2′), 1.69(t, 1H, J=12.0 Hz, 6′-OH).

¹³C NMR (100 MHz, CDCl₃); δ 138.7 (Ar-ipso), 138.1 (Ar-ipso), 138.1(Ar-ipso), 133.6 (C2), 128.4-127.6 (m, Ar), 118.3 (C3), 95.6 (C1′), 81.9(C3′), 79.9 (C2′), 77.3 (C4′), 75.7 (ArCH₂), 75.0 (ArCH₂), 73.2 (ArCH₂),70.8 (C5′), 68.2 (C1), 61.7 (C6′).

Example I-4 Step D;1-O-allyl-2,3,4-tri-O-benzyl-6-O-tosyl-α-D-glucopyranose (5)

To a solution of the compound (4) (25.1 g, 51.2 mmol) in anhydrouspyridine (250 ml) were added p-toluenesulfonyl chloride (14.6 g, 1.5equivalents) and 4-dimethylaminopyridine (626 mg, 0.1 equivalents), andthe reaction liquid was stirred at room temperature for 16 hours. Afterthe sufficient progress of the reaction was confirmed, water (10 ml) wasadded to stop the reaction, and the reaction liquid was concentratedunder reduced pressure. The residue was suspended in a minor amount ofethyl acetate, poured to 0.5 M hydrochloric acid (200 ml), and extractedwith ethyl acetate (3×200 ml). The organic layers were combined, washedwith a saturated sodium hydrogen carbonate solution (2×100 ml) andsaturated saline (2×100 ml), dried with sodium sulfate, filtered, andconcentrated under reduced pressure. The obtained residue wascrystallized twice from heated ethanol to obtain the title compound (5)in the form of colorless needle crystals (25.0 g). The filtrate wasconcentrated, purified with silica gel chromatography (hexane-ethylacetate, 5:1→4:1→3:1) to obtain the compound (5) (4.00 g). {29.0 g (45.0mmol) in total, 87.9%}.

[α]²⁵ _(D) +32.1° (c1.02 CHCl₃), LRMS m/z 667 (M+Na)⁺, mp 86-87^(L).

¹H NMR (400 MHz, CDCl₃); δ 7.76 (ddd, 2H, J=8.32, 1.96, 1.76 Hz, ArH),7.35-7.26 (m, 15H, ArH), 7.17-7.12 (m, 2H, ArH), 5.88 (dddd, 1H, J=17.2,10.3, 6.62, 5.24 Hz, H2), 5.28 (dq, 1H, J=17.2, 1.56 Hz, H3a), 5.20(ddt, 1H, J=10.3, 1.60, 1.12 Hz, H3b), 4.99 (d, 1H, J=10.9 Hz, ArCH₂),4.82 (d, 1H, J=10.6 Hz, ArCH₂), 4.78 (d, 1H, J=10.8 Hz, ArCH₂), 4.74 (d,1H, J=12.1 Hz, ArCH₂), 4.72 (d, 1H, J=3.58 Hz, H1′), 4.62 (d, 1H, J=12.1Hz, ArCH₂), 4.42 (d, 1H, J=10.6 Hz, ArCH₂), 4.22 (dd, 1H, J=10.5, 4.20Hz, H6′a), 4.16 (dd, 1H, J=10.5, 2.12 Hz, H6′b), 4.07 (ddt, 1H, J=12.9,5.24, 1.40 Hz, H1a), 3.98 (t, 1H, J=9.24 Hz, H3′), 3.93 (ddt, 1H,J=12.9, 6.64, 1.16 Hz, H1b), 3.81 (ddd, 1H, J=10.1, 4.12, 2.04 Hz, H5′),3.48 (dd, 1H, J=9.62, 3.58 Hz, H2′), 3.45 (dd, 1H, J=10.0, 8.90 Hz,H4′), 2.39 (s, 3H, Ts-Me).

¹³C NMR (100 MHz, CDCl₃); δ 144.8 (Ar-ipso), 138.5 (Ar-ipso), 137.9(Ar-ipso), 137.7 (Ar-ipso), 133.4 (C2), 132.8 (Ar-ipso), 129.8 (Ar),128.4-127.6 (m, Ar), 118.4 (C3), 95.4 (C1′), 81.8 (C3′), 79.6 (C2′),76.9 (C4′), 75.7 (ArCH₂), 75.0 (ArCH₂), 73.2 (ArCH₂), 68.6 (C5′), 68.5(C6′), 68.3 (C1), 21.6 (Ts-Me).

Example I-5 Step E;1-O-(2,3,4-tri-O-benzyl-6-O-tosyl-α-D-glucopyranosyl)-propane-1,3-diol(6)

To a solution of the compound (5) (29.0 g, 45.0 mmol) in anhydroustetrahydrofuran (THF, 150 ml), added was a solution of 0.5 M9-borabicyclo[3,3,1]nonane (9-BBN) in tetrahydrofuran (180 ml, 90.0mmol) at 0° C. in an argon atmosphere. After a lapse of 1 hour, thereaction liquid was returned to room temperature, and continuouslystirred for 10 hours. The reaction liquid was cooled again to 0° C., towhich water (20 ml) was added firstly, and then 3 M sodium hydroxidesolution (70 ml) and 35% hydrogen peroxide solution (70 ml) were addedsequentially. After a lapse of 1 hour, the reaction liquid was returnedto room temperature, and stirred for 12 hours. After the sufficientprogress of the reaction was confirmed, the solution was extracted withethyl acetate (3×100 ml), the organic layers were combined and washedwith saturated saline (2×100 ml), dried with sodium sulfate, filtered,and concentrated under reduced pressure. The obtained residue waspurified with silica gel chromatography (hexane-ethyl acetate,3:2→1:1→2:3) to obtain the title compound (6) in the form of a colorlessoily substance {28.2 g (42.5 mmol), 94.4%}.

[α]²⁴ _(D) +26.6° (c1.02 CHCl₃), LRMS m/z 685 (M+Na)⁺.

¹H NMR (400 MHz, CDCl₃); δ 7.76-7.74 (m, 2H, ArH), 7.35-7.26 (m, 15H,ArH), 7.16-7.12 (m, 2H, ArH), 4.94 (d, 1H, J=10.9 Hz, ArCH₂), 4.82 (d,1H, J=10.7 Hz, ArCH₂), 4.77 (d, 1H, J=10.9 Hz, ArCH₂), 4.75 (d, 1H,J=12.0 Hz, ArCH₂), 4.61 (d, 1H, J=12.0 Hz, ArCH₂), 4.61 (d, 1H, J=3.64Hz, H1′), 4.43 (d, 1H, J=10.7 Hz, ArCH₂), 4.20-4.13 (m, 2H, H6′a &H6′b), 3.92 (t, 1H, J=9.24 Hz, H3′), 3.84-3.74 (m, 4H, H1a & H3a & H3b &H5′), 3.48-3.40 (m, 3H, H1b & H2′ & H4′), 2.52 (t, 1H, J=4.74 Hz, 3-OH),2.39 (s, 3H, Ts-Me), 1.88-1.75 (m, 2H, H2a & H2b).

¹³C NMR (100 MHz, CDCl₃); δ 144.8 (Ar-ipso), 138.4 (Ar-ipso), 137.9(Ar-ipso), 137.6 (Ar-ipso), 132.7 (Ar-ipso), 129.8 (Ar), 128.5-127.6 (m,Ar), 97.1 (C1′), 81.8 (C3′), 79.5 (C2′), 76.8 (C4′), 75.6 (ArCH₂), 75.0(ArCH₂), 73.4 (ArCH₂), 68.7 (C5′), 68.6 (C6′), 67.5 (C1), 61.5 (C3),31.5 (C2), 21.6 (Ts-Me).

Example I-6 Step F;1-O-(2,3,4-tri-O-benzyl-6-thioacetyl-α-D-quinovopyranosyl)-propane-1,3-diol(7)

To a solution of the compound (6) (28.2 g, 42.5 mmol) in anhydrous DMF(300 ml), added was potassium thioacetate (7.28 g, 1.5 equivalents), andthe mixture was stirred at 90° C. for 3 hours. After the sufficientprogress of the reaction was confirmed, the reaction liquid was pouredto chilled water (900 ml), extracted with ethyl acetate (3×300 ml). Theorganic layers were combined and washed with saturated saline (2×200ml), dried with sodium sulfate, filtered, and concentrated under reducedpressure. The obtained residue was purified with silica gelchromatography (hexane-ethyl acetate, 2:1→3:2→1:1→2:3) to obtain thetitle compound (7) in the form of a light brown oily substance {21.9 g(38.6 mmol), 90.8%}.

[α]²³ _(D) +33.0° (c1.02 CHCl₃), LRMS m/z 584 (M+Na)⁺.

¹H NMR (400 MHz, CDCl₃); δ 7.37-7.24 (m, 15H, ArH), 4.95 (d, 1H, J=10.8Hz, ArCH₂), 4.89 (d, 1H, J=10.6 Hz, ArCH₂), 4.80 (d, 1H, J=10.8 Hz,ArCH₂), 4.77 (d, 1H, J=12.1 Hz, ArCH₂), 4.63 (d, 1H, J=12.0 Hz, ArCH₂),4.63 (d, 1H, J=3.52 Hz, H1′), 4.61 (d, 1H, J=10.7 Hz, ArCH₂), 3.94 (t,1H, J=9.22 Hz, H3′), 3.88 (ddd, 1H, J=9.86, 6.10, 4.88 Hz, H1a),3.83-3.73 (m, 3H, H3a & H3b & H5′), 3.50 (dd, 1H, J=9.60, 3.64 Hz, H2′),3.45 (ddd, 1H, J=9.92, 5.24, 2.28 Hz, H1b), 3.41 (dd, 1H, J=13.6, 3.00Hz, H6′a), 3.30 (dd, 1H, J=9.54, 9.06 Hz, H4′), 3.02 (dd, 1H, J=13.7,7.64 Hz, H6′b), 2.67 (br, 1H, 3-OH), 2.32 (s, 3H, SAc-Me), 1.92-1.78 (m,2H, H2a & H2b).

¹³C NMR (100 MHz, CDCl₃); δ 195.0 (SAc-C═O), 138.5 (Ar-ipso), 137.9(Ar-ipso), 137.8 (Ar-ipso), 128.5-127.6 (m, Ar), 96.9 (C1′), 81.8 (C3′),80.4 (C4′), 79.8 (C2′), 75.7 (ArCH₂), 75.2 (ArCH₂), 73.4 (ArCH₂), 69.5(C5′), 67.2 (C1), 61.5 (C3), 31.5 (C2), 30.8 (C6′), 30.5 (SAc-Me).

Example I-7 Step G; 3-O-(2,3,4-tri-O-benzyl-6-thioacetyl-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol (8)

To a solution of the compound (7) (21.9 g, 38.6 mmol) in anhydrousdichloromethane (200 ml), added were stearoyl chloride (15.2 g, 1.3equivalents) and anhydrous pyridine (5 ml), and the mixture was stirredat room temperature for 2 hours. After the sufficient progress of thereaction was confirmed, methanol (5 ml) was added to stop the reaction,and the mixture was concentrated under reduced pressure. The residue wassuspended in a minor amount of ethyl acetate, poured to water (200 ml),and extracted with ethyl acetate (3×100 ml). The organic layers werecombined and washed with saturated saline (2×100 ml), dried with sodiumsulfate, filtered, and concentrated under reduced pressure. The obtainedresidue was purified with silica gel chromatography (hexane-ethylacetate, 10:1→8:1→6:1) to obtain the title compound (8) in the form of acolorless oily substance {31.3 g (37.6 mmol), 97.4%}.

[α]²³ _(D) +29.5° (c1.01 CHCl₃), LRMS m/z 855 (M+Na)⁺.

¹H NMR (400 MHz, CDCl₃); δ 7.35-7.25 (m, 15H, ArH), 4.98 (d, 1H, J=10.8Hz, ArCH₂), 4.89 (d, 1H, J=10.6 Hz, ArCH₂), 4.80 (d, 1H, J=10.8 Hz,ArCH₂), 4.76 (d, 1H, J=12.0 Hz, ArCH₂), 4.66 (d, 1H, J=3.60 Hz, H1′),4.63 (d, 1H, J=12.1 Hz, ArCH₂), 4.62 (d, 1H, J=10.7 Hz, ArCH₂),4.23-4.14 (m, 2H, H1a & H1b), 3.96 (t, 1H, J=9.20 Hz, H3′), 3.78 (ddd,1H, J=9.68, 7.56, 2.92 Hz, H5′), 3.72 (dt, 1H, J=10.0, 6.40 Hz, H3a),3.50 (dd, 1H, J=9.64, 3.60 Hz, H2′), 3.43 (dt, 1H, J=9.72, 6.36 Hz,H3b), 3.41 (dd, 1H, J=13.6, 2.96 Hz, H6′a), 3.31 (t, 1H, J=9.24 Hz,H4′), 3.05 (dd, 1H, J=13.6, 7.56 Hz, H6′b), 2.33 (s, 3H, SAc-Me), 2.29(t, 2H, J=7.68 Hz, COCH₂), 1.95 (f, 2H, J=6.40 Hz, H2a & H2b), 1.61 (f,2H, J=7.24 Hz, COCH₂CH₂), 1.25 (br, 28H, —CH₂—), 0.88 (t, 3H, J=6.84 Hz,Me).

¹³C NMR (100 MHz, CDCl₃); δ 194.8 (SAc-C═O), 173.8 (C═O), 138.6(Ar-ipso), 138.1 (Ar-ipso), 137.8 (Ar-ipso), 128.4-127.6 (m, Ar), 96.8(C1′), 81.7 (C3′), 80.4 (C4′), 80.1 (C2′), 75.7 (ArCH₂), 75.2 (ArCH₂),73.2 (ArCH₂), 69.4 (C5′), 64.6 (C3), 61.2 (C1), 34.3 (COCH₂), 31.9(—CH₂—), 30.9 (C6′), 30.5 (SAc-Me), 29.7-29.2 (m, —CH₂—), 28.7 (C2),25.0 (COCH₂CH₂), 22.7 (—CH₂—), 14.1 (Me).

Example I-8 Step H;3-O-(2,3,4-tri-O-benzyl-6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolsodium salt (9)

To a solution of the compound (8) (31.3 g, 37.6 mmol) in acetic acid(450 ml) were added Oxone® (46.2 g) and potassium acetate (11.3 g), andthe mixture was vigorously stirred at room temperature 48 hours. Afterthe sufficient progress of the reaction was confirmed, the reactionliquid was poured to a chilled 7.5 M sodium hydroxide solution (1000ml), and extracted with ethyl acetate (4×200 ml). The organic layerswere combined, washed with saturated sodium hydrogen carbonate solution(2×200 ml) and saturated saline (2×200 ml), dried with sodium sulfate,filtered, and concentrated under reduced pressure. The obtained residuewas purified with silica gel chromatography (dichloromethane-methanol,15:1→10:1→8:1) to obtain the title compound (9) in the form of acolorless waxy substance {28.7 g (33.3 mmol), 88.6%}.

[α]²³ _(D) +29.0° (c1.16 CHCl₃), LRMS m/z 837 (M-Na)⁻.

¹H NMR (400 MHz, DMSO-d₆); δ 7.36-7.22 (m, 15H, ArH), 4.85 (d, 1H,J=11.2 Hz, ArCH₂), 4.81 (d, 1H, J=3.72 Hz, H1′), 4.79 (d, 1H, J=11.4 Hz,ArCH₂), 4.69 (d, 1H, J=11.2 Hz, ArCH₂), 4.65 (d, 1H, J=12.0 Hz, ArCH₂),4.61 (d, 1H, J=12.0 Hz, ArCH₂), 4.58 (d, 1H, J=11.4 Hz, ArCH₂),4.19-4.10 (m, 2H, H1a & H1b), 4.05-3.96 (m, 2H, H3a & H5′), 3.79 (t, 1H,J=9.14 Hz, H3′), 3.47 (dd, 1H, J=9.56, 3.60 Hz, H2′), 3.38 (dt, 1H,J=10.1, 6.20 Hz, H3b), 3.20 (dd, 1H, J=9.80, 9.00 Hz, H4′), 2.94 (dd,1H, J=13.9, 1.16 Hz, H6′a), 2.63 (dd, 1H, J=14.0, 9.06 Hz, H6′b), 2.29(t, 2H, J=7.38 Hz, COCH₂), 1.86 (f, 2H, J=6.36 Hz, H2a & H2b), 1.52 (f,2H, J=7.12 Hz, COCH₂CH₂), 1.23 (br, 28H, —CH₂—), 0.85 (t, 3H, J=6.84 Hz,Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 172.9 (C═O), 138.9 (Ar-ipso), 138.6(Ar-ipso), 138.6 (Ar-ipso), 128.2-127.3 (m, Ar), 95.0 (C1′), 81.4 (C3′),80.5 (C4′), 80.0 (C2′), 74.4 (ArCH₂), 73.7 (ArCH₂), 71.4 (ArCH₂), 67.3(C5′), 63.4 (C3), 61.5 (C1), 52.8 (C6′), 33.6 (COCH₂), 31.3 (—CH₂—),29.0-28.4 (m, C2 & —CH₂—), 24.5 (COCH₂CH₂), 22.1 (—CH₂—), 13.9 (Me).

Example I-9 Step I;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt (10)

To a solution of the compound (9) (28.7 g, 33.3 mmol) in ethanol (400ml) and dichloromethane (150 ml) was added 10% Palladium activatedcarbon (7.00 g), and the mixture was stirred at room temperature for 48hours in a hydrogen gas atmosphere. After the sufficient progress of thereaction was confirmed, palladium activated carbon was removed byfiltration, and the filtrate was concentrated under reduced pressure.The obtained residue was purified with silica gel chromatography(dichloromethane-methanol, 10:1→5:1→3:1→2:1→1:1), and precipitated from98% heated ethanol to obtain the title compound (10) in the form of acolorless powder {15.6 g (26.4 mmol), 79.4%}.

[α]²² _(D) +49.6° (c1.00H₂O), LRMS m/z 567 (M-Na)⁻, HRMS calcd forC₂₇H₅₁O₁₀S (M-Na)⁻ 567.3208, found 567.3210.

¹H NMR (400 MHz, DMSO-d₆); δ 5.40 (d, 1H, J=3.48 Hz, 4′-OH), 4.58 (d,1H, J=4.64 Hz, 3′-OH), 4.56 (d, 1H, J=3.72 Hz, H1′), 4.45 (d, 1H, J=6.52Hz, 2′-OH), 4.15-4.06 (m, 2H, H1a & H1b), 3.84-3.78 (m, 2H, H3a & H5′),3.42-3.34 (m, 2H, H3b & H3′), 3.19 (ddd, 1H, J=9.62, 6.50, 3.76 Hz,H2′), 2.98-2.91 (m, 2H, H4′ & H6′a), 2.63 (dd, 1H, J=14.0, 6.00 Hz,H6′b), 2.28 (t, 2H, J=7.40 Hz, COCH₂), 1.86-1.80 (m, 2H, H2a & H2b),1.55-1.48 (m, 2H, COCH₂CH₂), 1.24 (br, 28H, —CH₂—), 0.86 (t, 3H, J=6.84Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 172.8 (C═O), 98.2 (C1′), 74.7 (C4′), 73.1(C3′), 71.8 (C2′), 68.2 (C5′), 63.4 (C3), 61.2 (C1), 55.1 (C6′), 33.4(COCH₂), 31.2 (—CH₂—), 28.9-28.4 (m, C2 & —CH₂—), 24.4 (COCH₂CH₂), 22.0(—CH₂—), 13.8 (Me).

2.15 g of3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt was dissolved in 60 ml of water, adsorbed to a WAKOGEL® 100C18(manufactured by Wako Pure Chemical Industries, Ltd.) column, and 500 mlof 1% calcium chloride solution was poured into the column forsubstitution, and washed with 500 ml of distilled water. Thereafter,elution was performed with 200 ml each of 50%, 80%, and 100% methanol,and reprecipitated from 98% heated ethanol to obtain 1.47 g of3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol calciumsalt.

Although not shown in Examples, with the same column treatment, amagnesium or potassium salt can be obtained through substitution with amagnesium chloride or potassium chloride solution.

Example II

As other examples of α-sulfoquinovosylacyl propanediol compounds,described below are the α anomer compounds having 22, 14, 10, 6, 2, and1 carbon atoms within the acyl residue of the fatty acid.

Example II-1 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-decanoyl-1,3-diolsodium salt

The title compound was synthesized in the same manner as Example I,except that decanoyl chloride was used as the fatty acid derivative inthe step G.

[α]²² _(D) +57.9° (c 0.76, H₂O), LRMS m/z 455 (M-Na)⁻, HRMS calcd forC₁₉H₃₅O₁₀S (M-Na)⁻ 455.1956, found 455.1954. ¹H NMR (400 MHz, DMSO-d₆);δ 5.40 (d, 1H, J=3.1 Hz, 4′-OH), 4.65 (d, 1H, J=4.7 Hz, 3′-OH), 4.56 (d,1H, J=3.7 Hz, H1′), 4.52 (d, 1H, J=6.48 Hz, 2′-OH), 4.14-4.08 (m, 2H,H1a & H1b), 3.84-3.78 (m, 2H, H3a & H5′), 3.41-3.33 (m, 2H, H3b & H3′),3.21-3.16 (m, 1H, H2′), 2.97-2.92 (m, 2H, H4′ & H6′a), 2.61 (dd, 1H,J=14.0, 6.2 Hz, H6′b), 2.29 (t, 2H, J=7.4 Hz, COCH₂), 1.84-1.81 (m, 2H,H2a & H2b), 1.53-1.50 (m, 2H, COCH₂CH₂), 1.25 (br, 12H, —CH₂—), 0.86 (t,3H, J=6.8 Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 173.1 (C═O), 98.4 (C1′), 74.8 (C4′), 73.2(C3′), 71.9 (C2′), 68.4 (C5′), 63.5 (C3), 61.4 (C1), 55.2 (C6′), 33.6(COCH₂), 31.4 (—CH₂—), 29.0-28.6 (m, C2 & —CH₂—), 24.6 (COCH₂CH₂), 22.2(—CH₂—), 14.1 (Me).

Example II-2 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-myristoyl-1,3-diolsodium salt

The title compound was synthesized in the same manner as Example I,except that myristoyl chloride was used as the fatty acid derivative inthe step G.

[α]²³ _(D) +49.7° (c 0.67, H₂O), LRMS m/z 511 (M-Na)⁻, HRMS calcd forC₂₃H₄₃O₁₀S (M-Na)⁻ 511.2582, found 511.2596.

¹H NMR (400 MHz, DMSO-d₆); δ 5.41 (br, 1H, 4′-OH), 4.63-4.61 (m, 1H,3′-OH), 4.55 (d, 1H, J=3.7 Hz, H1′), 4.50-4.48 (m, 1H, 2′-OH), 4.13-4.07(m, 2H, H1a & H1b), 3.83-3.77 (m, 2H, H3a & H5′), 3.41-3.33 (m, 2H, H3b& H3′), 3.20-3.15 (m, 1H, H2′), 2.98-2.91 (m, 2H, H4′ & H6′a), 2.64-2.59(m, 1H, H6′b), 2.28 (t, 2H, J=7.4 Hz, COCH₂), 1.86-1.79 (m, 2H, H2a &H2b), 1.53-1.49 (m, 2H, COCH₂CH₂), 1.24 (br, 20H, —CH₂—), 0.85 (t, 3H,J=6.8 Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 173.0 (0=0), 98.4 (C1′), 74.8 (C4′), 73.2(C3′), 71.9 (C2′), 68.4 (C5′), 63.5 (C3), 61.4 (C1), 55.3 (C6′), 33.6(COCH₂), 31.4 (—CH₂—), 29.1-28.6 (m, C2 & —CH₂—), 24.6 (COCH₂CH₂), 22.2(—CH₂—), 14.0 (Me).

Example II-3 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-behenoyl-1,3-diolsodium salt

The title compound was synthesized in the same manner as Example I,except that behenoyl chloride was used as the fatty acid derivative inthe step G.

[α]²³ _(D) +46.3° (c 0.51, CHCl₃:MeOH:H₂O=30:15:2), LRMS m/z 623(M-Na)⁻, HRMS calcd for C₂₁H₅₉O₁₀S (M-Na)⁻ 623.3834, found 623.3835.

¹H NMR (400 MHz, DMSO-d₆); δ 5.38-5.37 (m, 1H, 4′-OH), 4.78-4.77 (m, 1H,3′-OH), 4.63 (d, 1H, J=6.52 Hz, 2′-OH), 4.56 (d, 1H, J=3.72 Hz, H1′),4.14-4.07 (m, 2H, H1a & H1b), 3.86-3.78 (m, 2H, H3a & H5′), 3.43-3.32(m, 2H, H3b & H3′), 3.22-3.17 (m, 1H, H2′), 2.98-2.90 (m, 2H, H4′ &H6′a), 2.60 (dd, 1H, J=14.0, 6.7 Hz, H6′b), 2.28 (t, 2H, J=7.22 Hz,COCH₂), 1.86-1.79 (m, 2H, H2a & H2b), 1.52-1.49 (m, 2H, COCH₂CH₂), 1.23(br, 36H, —CH₂—), 0.85 (t, 3H, J=6.1 Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 173.4 (C═O), 98.5 (C1′), 74.7 (C4′), 73.4(C3′), 72.2 (C2′), 68.6 (C5′), 63.6 (C3), 61.8 (C1), 55.0 (C6′), 33.9(COCH₂), 31.7 (—CH₂—), 29.4-28.8 (m, C2 & —CH₂—), 24.9 (COCH₂CH₂), 22.5(—CH₂—), 14.3 (Me).

Example II-43-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-hexanoyl-propane-1,3-diol calciumsalt (10)

A sodium salt was synthesized in the same manner as Example I, exceptthat hexanoyl chloride was used as the fatty acid derivative in the stepG.

LRMS m/z 399 (M-Na)⁻

¹H NMR (400 MHz, DMSO-d₆); δ 5.34 (br, 1H, 4′-OH), 4.56 (d, 1H, J=4.0Hz, H1′), 4.53 (br, 1H, 3′-OH), 4.41 (d, 1H, J=6.4 Hz, 2′-OH), 4.10 (t,2H, J=6.6 Hz, H1a & H1b), 3.83-3.77 (m, 2H, H3a & H5′), 3.41-3.33 (m,2H, H3b & H3′), 3.21-3.16 (m, 1H, H2′), 2.98-2.92 (m, 2H, H4′ & H6′a),2.63 (dd, 1H, J=14.0, 6.0 Hz, H6′b), 2.27 (t, 2H, J=7.2 Hz, COCH₂), 1.82(tt, J=6.4, 6.4 Hz, 2H, H2a & H2b), 1.52 (tt, J=7.2, 6.8 Hz, 2H,COCH₂CH₂), 1.30-1.26 (m, 4H, —CH₂—), 0.85 (t, 3H, J=6.6 Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 173.0 (C═O), 98.3 (C1′), 74.7 (C4′), 73.2(C3′), 71.9 (C2′), 68.3 (C5′), 63.5 (C3), 61.3 (C1), 55.2 (C6′), 33.5(COCH₂), 30.7 (—CH₂—), 28.6 (C2), 24.1 (COCH₂CH₂), 21.7 (—CH₂—), 13.7(Me).

The sodium salt was further subjected to ion exchange treatment toobtain the title compound.

Example II-53-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-acetyl-propane-1,3-diol calciumsalt

A sodium salt was synthesized in the same manner as Example I, exceptthat acetyl chloride was used as the fatty acid derivative in the stepG.

LRMS m/z 343 (M-Na)⁻

¹H NMR (400 MHz, DMSO-d₆); δ 5.47-5.46 (m, 1H, 4′-OH), 4.57 (d, 1H,J=3.6 Hz, H1′), 4.50-4.49 (br, 1H, 3′-OH), 4.39-4.38 (br, 1H, 2′-OH),4.10 (t, 2H, J=6.8 Hz, H1), 3.83-3.76 (m, 2H, H3a & H5′), 3.42-3.34 (m,2H, H3b & H3′), 3.20-3.16 (m, 1H, H2′), 2.98 (ddd, 1H, J=9.0, 9.0, 3.2Hz, H4′), 2.88 (dd, 1H, J=13.6, 5.6 Hz, H6′a), 2.62 (dd, 1H, J=14.0, 5.6Hz, H6′b), 2.00 (s, 3H, Me), 1.835 (tt, 1H, J=6.4, 6.4 Hz, H2).

¹³C NMR (100 MHz, DMSO-d₆); δ 170.4 (C═O), 98.3 (C1′), 74.6 (C4′), 73.2(C3′), 71.9 (C2′), 68.3 (C5′), 63.5 (C3), 61.5 (C1), 55.0 (C6′), 28.5(C2), 20.7 (Me).

The sodium salt was further subjected to ion exchange treatment toobtain the title compound.

Example II-63-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diol sodiumsalt (10)

The title compound was obtained through the steps A-1 to F of Example I,followed by the following steps J to L.

Step J;3-O-(2,3,4-tri-O-benzyl-6-sulfo-α-D-quinovopyranosyl)-propane-1,3-diolsodium salt (8″)

To a solution of the compound (7) (542 mg, 956 μmol) in acetic acid (5.5g), added were Oxone® (1.8 g) and potassium acetate (68 mg), and themixture was vigorously stirred at room temperature for 48 hours. Afterthe sufficient progress of the reaction was confirmed, the reactionliquid was poured to a chilled 7.5 M sodium hydroxide (13 ml) solution,and extracted with ethyl acetate (3×10 ml). The organic layers werecombined, washed with saturated sodium hydrogen carbonate solution (2×10ml) and saturated saline (2×10 ml), dried with sodium sulfate, filtered,and concentrated under reduced pressure. The concentrated residue waspurified with silica gel chromatography (chloroform-methanol,10:1→8:1→6:1→4:1→2:1→1:1) to obtain the title compound 8″ in the form ofa colorless waxy substance [401 mg (675 mmol), 70.7%].

LRMS m/z 571 (M-Na)⁻

¹H NMR (400 MHz, CD₃OD+CDCl₃); δ 7.37-7.26 (m, 15H, ArH), 4.96 (d, 1H,J=11.2 Hz, ArCH₂), 4.89 (d, 1H, J=11.2 Hz, ArCH₂), 4.80 (d, 1H, J=3.6Hz, H1′), 4.78 (d, 1H, J=10.4 Hz, ArCH₂), 4.75 (d, 1H, J=11.6 Hz,ArCH₂), 4.66 (d, 1H, J=11.6 Hz, ArCH₂), 4.62 (d, 1H, J=11.2 Hz, ArCH₂),4.24-4.19 (m, 1H, 5′), 4.09 (ddd, 1H, J=9.6, 8.4, 5.2 Hz, H1a), 3.97(dd, 1H, J=9.2, 9.2 Hz, H3′), 3.80 (ddd, 1H, J=11.3, 8.0, 4.0 Hz, H3a),3.68-3.62 (m, 1H, H3b), 3.56 (dd, 1H, J=9.6, 3.6 Hz, H2′), 3.46 (ddd,1H, J=9.8, 5.4, 5.4 Hz, H1b), 3.32-3.23 (m, 2H, H6′a & H4′), 2.93 (dd,1H, J=14.0, 9.8 Hz, H6′b), 1.98-1.81 (m, 2H, H2a & H2b).

¹³C NMR (100 MHz, CD₃OD+CDCl₃); δ 139.0 (Ar-ipso), 138.5 (Ar-ipso),138.4 (Ar-ipso), 128.9-128.1 (m, Ar), 96.8 (C1′), 82.4 (C3′), 81.0(C4′), 80.6 (C2′), 76.1 (ArCH₂), 75.5 (ArCH₂), 73.6 (ArCH₂), 67.9 (C5′),65.5 (C1), 59.6 (C3), 52.8 (C6′), 32.6 (C2).

Step K; 3-O-(6-sulfo-α-D-quinovopyranosyl)-propane-1,3-diol sodium salt(9″)

To a solution of the compound (8″) (534 mg, 898 μmol) in methanol (20ml) and chloroform (5.0 ml), added was 10% palladium activated carbon(135 mg), and the mixture was stirred at room temperature for 16 hoursin a hydrogen gas atmosphere. After the sufficient progress of thereaction was confirmed, palladium activated carbon was collected byfiltration, and the filtrate was concentrated under reduced pressure. Tothe obtained residue, added were methanol (20 ml) and toluene (20 ml),the mixture was vigorously stirred, and the solvent was removed byevaporation under reduced pressure to obtain a mixture in the form of acolorless liquid (320 mg). The presence of the title compound in themixture was confirmed by LRMS. The mixture containing the title compound(9″) was then subjected to the subsequent reaction.

LRMS m/z 301 (M-Na)

Step L;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diol sodiumsalt (10)

A mixture containing the compound (9″) (70 mg),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI.HCl)(93 mg, 487 μmol), and 4-dimethylaminopyridine (12 mg, 97 μmol) weredissolved in anhydrous N,N-dimethylformamide (DMF, 10 ml), formic acid(14 mg, 259 μmol) was added dropwise to the solution under cooling withice, and allowed to react at room temperature for 18 hours. After thesufficient progress of the reaction was confirmed, water (1.0 ml) waspoured to the reaction liquid to stop the reaction, and then thesolution was concentrated under reduced pressure. The obtained residuewas purified with silica gel chromatography (chloroform-methanol-water,3:1:0.1→2:1:0.1→1:1:0.1) to obtain the title compound 10 in the form ofa colorless oily substance [12 mg (33 μmol), 16.7%].

LRMS m/z 329 (M-Na)⁻

¹H NMR (400 MHz, DMSO-d₆); δ 8.18 (s, 1H, O═CH), 4.56 (d, 1H, J=3.6 Hz,H1′), 4.20 (t, 2H, J=6.8 Hz, H1a & H1b), 3.86-3.7.8 (m, 2H, H3a & H5′),3.41-3.31 (m, 2H, H3b & H3′), 3.18 (dd, 1H, J=9.6, 4.0 Hz, H2′),3.03-2.90 (m, 2H, H4′ & H6′a), 2.63-2.58 (m, 1H, H6′b), 1.86 (tt, J=6.4,6.4 Hz, 2H, H2a & H2b)

¹³C NMR (100 MHz, DMSO-d₆); δ 162.2 (C═O), 98.4 (C1′), 74.7 (C4′), 73.2(C3′), 71.9 (C2′), 68.4 (C5′), 63.3 (C3), 61.2 (C1), 55.1 (C6′), 26.1(C2).

Example III

Another example of the process for preparing the β-sulfoquinovosylacylpropanediol compound according to the present invention is describedbelow.

Example III-13-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-oleoyl-propane-1,3-diol sodiumsalt

The title compound was synthesized through the procedure according tothe following scheme.

A′) acetic anhydride, sodium acetate, heating and boiling, 55.3%;

B′) hydrobromic acid-acetic acid solution, dichloromethane, roomtemperature, 6 hours, 58.5%;

C′) allyl alcohol, cyanide mercury, dichloromethane, room temperature,16 hours, 64.4%;

D′) D′-1. sodium methoxide, methanol, room temperature, 4 hours;

D′-2. p-anisaldehyde dirnethyl acetal, p-toluenesulfonic acidmonohydrate, acetonitrile, 40° C., 16 hours,: 95.3%;

E′) p-methoxybenzyl chloride, sodium hydroxide, N,N-dimethylformamide,room temperature, 16 hours, 92.0%;

F′) aluminum lithium hydride, aluminum chloride, dichloromethane,diethyl ether, 0° C., 1 hour, 73.3%;

G′) p-toluenesulfonyl chloride, 4-dimethylaminopyridine, pyridine, roomtemperature, 16 hours, 85.9%;

H′) 9-borabicyclononane, tetrahydrofuran, room temperature, 16 hours;water, sodium hydroxide, hydrogen peroxide water, room temperature, 4hours, 93.5%

I′) sodium sulfite, ethanol, water, heating under reflux, 72 hours,90.2%;

J′) oleic acid anhydride, 4-dimethylaminopyridine, pyridine,dichloromethane, heating under reflux, 16 hours, 67.6%; and

K′) 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, dichlorometharie,methanol, water, room temperature, 4 hours, 55.9%.

[α]²¹ _(D) −3.1° (c1.00 CH₃OH), LRMS m/z 565 (M-Na)⁻, HRMS calcd forC₂₇H₄₉O₁₀S (M-Na)⁻ 565.3051, found 565.3059.

¹H NMR (400 MHz, CD₃OD); δ 5.37-5.30 (m, 2H, —CH═CH—), 4.27 (d, 1H,J=7.84 Hz, H1′), 4.23-4.13 (m, 2H, H1a & H1b), 4.01-3.96 (m, 1H, H3a),3.72 (ddd, 1H, J=9.64, 8.62, 2.20 Hz, H5′), 3.68-3.62 (m, 1H, H3b), 3.38(dd, 1H, J=14.4, 2.20 Hz, H6′a), 3.36 (t, 1H, J=9.08 Hz, H3′), 3.19 (dd,1H, J=9.20, 7.88 Hz, H2′), 3.13 (t, 1H, J=9.28 Hz, H4′), 2.98 (dd, 1H,J=14.4, 8.62 Hz, H6′b), 2.31 (t, 2H, J=7.46 Hz, COCH₂), 2.04-2.00 (m,4H, —CH₂CH═CHCH₂—), 1.97-1.90 (m, 2H, H2a & H2b), 1.62-1.56 (m, 2H,COCH₂CH₂), 1.31-1.29 (br, 0.20H, —CH₂—), 0.89 (t, 3H, J=6.84 Hz, Me).

¹³C NMR (100 MHz, CD₃OD); δ 175.7 (0=0), 130.9 (—CH═CH—), 130.8(—CH═CH—), 104.2 (C1′), 77.9 (C3′), 75.1 (C2′), 74.7 (C4′), 73.7 (C5′),67.3 (C3), 62.8 (C1), 54.3 (C6′), 35.1 (COCH₂), 33.1 (—CH₂—), 30.8-30.1(m, C2 & —CH₂—), 28.1 (—CH₂CH═CHCH₂—), 26.1 (COCH₂CH₂), 23.8 (—CH₂—),14.5 (Me).

Example III-23-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt

The title compound was synthesized in the same manner as Example III-1,except that stearoyl chloride was used in place of oleic acid anhydride.

[α]²² _(D) −4.7° (c1.00H₂O), LRMS m/z 567 (M-Na)⁻, HRMS calcd forC₂₇H₅₁O₁₀S (M-Na)⁻ 567.3208, found 567.3211.

¹H NMR (400 MHz, DMSO-d₆); δ 5.56 (d, 1H, J=3.16 Hz, 4′-OH), 4.81 (d,1H, J=4.92 Hz, 2′-OH), 4.74 (d, 1H, J=4.64 Hz, 3′-OH), 4.09 (d, 1H,J=7.76 Hz, H1′), 4.07 (t, 2H, J=6.60 Hz, H1a & H1b), 3.77 (dt, 1H,J=10.2, 6.27 Hz, H3a), 3.54-3.45 (m, 2H, H3b & H5′), 3.13 (dt, 1H,J=8.80, 4.68 Hz, H3′), 2.99 (dt, 1H, J=9.14, 3.08 Hz, H4′), 2.97-2.91(m, 2H, H2′ & H6′a), 2.68 (dd, 1H, J=13.9, 5.24 Hz, H6′b), 2.27 (t, 2H,J=7.40 Hz, COCH₂), 1.86-1.78 (m, 2H, H2a & H2b), 1.54-1.47 (m, 2H,COCH₂CH₂), 1.24 (br, 28H, —CH₂—), 0.86 (t, 3H, J=6.88 Hz, Me).

¹³C NMR (100 MHz, DMSO-d₆); δ 172.9 (0=0), 102.8 (C1′), 76.1 (C3′), 74.6(C4′), 73.4 (C2′), 72.5 (C5′), 65.2 (C3), 61.2 (C1), 55.6 (C6′), 33.6(COCH₂), 31.3 (C2), 29.0-28.5 (m, —CH₂—), 24.5 (COCH₂CH₂), 22.1 (—CH₂—),13.9 (Me).

Analysis Example IV Example IV-1 Analysis with High Performance LiquidChromatography and Mass Spectrometry

The 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolsodium salt and 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-glycerolsodium salt were separated and detected by high performance liquidchromatography and electrospray mass spectrometry.

The test substance was dissolved in 5% acetonitrile in 5 mmol/l ammoniumacetate aqueous solution, diluted with the solvent to an intendedconcentration, and then analyzed by high performance liquidchromatography equipped with CapCellPak® C18MG (column size; 2.0×50 mm,manufactured by Shiseido Co., Ltd.). The separation conditions were asfollows: the column temperature was 40° C., the flow rate was 0.2 ml perminute, and elution was conducted over a period of 20 minutes with alinear concentration gradient of 50% to 70% of acetonitrile withreference to the above-described solvent.

The eluted test substance was detected with a Bruker Esquire 3000 plusion mass spectrometer, and the detection ion mode was total ionchromatography (TIC), and the detection mass range was m/z=100 to 1000.

FIGS. 1 and 2 show the chromatograms of the test substance.

The analysis result indicates that, as shown in FIG. 1, the3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt exhibited a single peak, while the3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-glycerol sodium saltshown in FIG. 2 exhibited minor peaks representing a structural isomerat 6.8 minutes (peak No. 1) and 7.3 minutes (peak No. 2), which suggestsacyl transfer from the 1-position to 2-position in the glycerol moiety,and major peaks representing a diastereo isomer (diastereomer) αSQMGC18:0 at 7.6 minutes (peak No. 3) and 7.8 minutes (peak No. 4).

These results indicate that the3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt according to an aspect of the present invention has a very highpurity in comparison with a known compound,3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-glycerol sodium salt.

Example IV-2 Solubility Measurement

1 g each of the sodium salt and calcium salt of3-0-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol wasplaced in 5 ml of distilled water (manufactured by Otsuka PharmaceuticalCo., Ltd.), strongly shaken at 25° C.; they were immediately dissolved.This fact suggests that the substance is evaluated as “readily soluble”by the criteria described in the general rules Japanese Pharmacopeia.

These results indicate that αSQAP has very high solubility. In addition,although not shown herein, SQAP series according to the presentinvention other than the salts of3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol alsohave high solubility. Such high solubility facilitates dissolution of anecessary amount of the substance in a small amount of a solvent. As aresult of this, for example, an injection to be administered to asubject can be readily prepared. In addition, such high water solubilityis advantageous in preparation of injections, as well as other variousformulations such as oral agents.

Pharmacological Tests.

The pharmacological activity of the sulfoquinovosylacyl propanediolcompound according to the present invention was examined.

Example V Radiosensitizing Effect Test

The radiosensitizing effect was examined through tumor-bearing mouseexperiment.

Example V-1 Human Esophageal Squamous Cell Carcinoma (No. 1)

Human esophageal squamous cell carcinoma cells TE-8 were transplantedinto the right femoral region of KSN nude mice in a ratio of 1×10⁶ cellsper individual. Subsequently, the mice were bred for about 14 days toform a tumor mass of about 150 mm³ in each individual. Thereafter, fourmice were assigned to each of the following groups (1) to (4):

(1) non-administered, un-irradiated group (in FIG. 3, indicated withwhite squares);

(2) non-administered, radiotherapy-treated group (in FIG. 3, indicatedwith white triangles);

(3) αSQAP C18:0-administered, un-irradiated group (in FIG. 3, indicatedwith black circles); and

(4) αSQAP C18:0-administered, radiotherapy-treated group (in FIG. 3,indicated with black rhombuses).

The drug was administered from Day 1 to Day 5, 2 mg/kg once a day. Thesubjects were exposed to radiation emitted from an X-ray generator(HS-225, manufactured by Shimadzu Co., Ltd.) at a dose of 2 Gy on Day 1and Day 4. The tumor volume was calculated according to the calculationformula: (minor axis)²×major axis×0.5. The results are shown in FIG. 3.

In all the groups, the tumor volume steadily increased from the start toend of the test. However, from about Day 10, the increment of the tumorvolume in the groups (2) to (4) fell below that in the (1)non-administered, un-irradiated group. In addition, suppression of theincrease of the tumor volume in the (2) non-administered,radiotherapy-treated group and (3) αSQAP C18:0-administered,un-irradiated group was at the same level. The increase of the tumorvolume was most suppressed in the (4) αSQMG C18:0-administered,radiotherapy-treated group in comparison with other groups.

Example V-2 Human Esophageal Squamous Cell Carcinoma (No. 2)

This experiment was conducted in the same manner as Example V-1, exceptthat the drug dose administered from Day 1 to Day 5 was 1 mg/kg once aday, and the radiation dose was 4 Gy, and the tumor volume was measured.The results are shown in FIG. 4.

Details about the groups are as follows:

(1) non-administered, un-irradiated group (in FIG. 4, indicated withblack rhombuses);

(2) non-administered, radiotherapy-treated group (in FIG. 4, indicatedwith black squares);

(3) αSQAP C18:0-administered, un-irradiated group (in FIG. 4, indicatedwith white rhombuses); and

(4) αSQAP C18:0-administered, radiotherapy-treated group (in FIG. 4,indicated with white squares).

The results indicate that, in all the groups, the tumor volume increasedwith the lapse of time. The increment in the tumor volume in the groups(2) to (4) was smaller than that in the (1) non-administered,un-irradiated group. In addition, the increase of the tumor volume wasmost strongly suppressed in the (4) αSQAP C18:0-administered,radiotherapy-treated group in comparison with other groups.

Example V-3 Human Colonic Adenocarcinoma

Human colonic adenocarcinoma cells SW480 were transplanted into theright femoral region of KSN nude mice in a ratio of 1×10⁶ cells perindividual. Subsequently, the mice were bred for about 14 days to form atumor mass of about 150 mm³ in each individual.

Thereafter, four mice were assigned to each of the three groups (1) to(3):

(1) non-administered, un-irradiated group (in FIG. 5, indicated withwhite rhombuses);

(2) non-administered, radiotherapy-treated group (in FIG. 5, indicatedwith black squares); and

(3) αSQAP C18:0-administered, radiotherapy-treated group (in FIG. 5,indicated with black triangles).

The drug was administered from Day 1 to Day 5, 2 mg/kg once a day. Thesubjects were exposed to radiation emitted from an X-ray generator(HS-225, manufactured by Shimadzu Co., Ltd.) at a dose of 2 Gy on Day 1and Day 4. The tumor volume was calculated according to the calculationformula: (minor axis)²×major axis×0.5. The results are shown in FIG. 5.

The results indicate that, in all the groups, the tumor volume increasedwith the lapse of time. However, the increase of the tumor volume in the(1) non-administered, un-irradiated group and (2) non-administered,radiotherapy-treated group was alike, but the increase of the tumorvolume in the (3) αSQAP C18:0-administered, radiotherapy-treated groupwas suppressed from the initial stage of the experiment, and theincrease of the tumor volume was markedly suppressed in general.

The following Examples V-4, 5, 6, and Examples VI to VIII used an SQAPcompound which had been calcium (salt)-substituted through ion exchangetreatment.

Example V-4 Human Colonic Adenocarcinoma

Human colonic adenocarcinoma cells SW480 were transplanted into theright femoral region of KSN nude mice in a ratio of 2×10⁶ cells perindividual. After a tumor mass of about 50 mm³ was formed in eachindividual, four mice were assigned to each of the four groups (1) to(4):

(1) non-administered, un-irradiated group (in FIG. 6, indicated withblack circles);

(2) non-administered, radiotherapy-treated group (in FIG. 6, indicatedwith black squares);

(3) αSQAP C18:0-administered, un-irradiated group (in FIG. 6, indicatedwith white triangles); and

(4) αSQAP C18:0-administered, radiotherapy-treated group (in FIG. 6,indicated with white squares).

The drug was administered from the tail vein from Day 1 to Day 5, 1mg/kg once a day. The subjects were exposed to radiation emitted from anX-ray generator (HS-225, manufactured by Shimadzu Co., Ltd.) at a doseof 2 Gy on Day 1 and Day 4.

The results are shown in FIG. 6, indicating that the tumor volumeincreased with time in all the groups. However, the increase of thetumor volume was most suppressed in the (4) αSQAP C18:0-administered,radiotherapy-treated group in comparison with other groups.

Example V-5 Human Esophageal Squamous Cell Carcinoma

Human esophageal squamous cell carcinoma cells TE-8 were transplantedinto the right femoral region of KSN nude mice in a ratio of 1×10⁶ cellsper individual. After a tumor mass of about 50 mm³ was formed in eachindividual, four mice were assigned to each of the four groups (1) to(4):

(1) non-administered, un-irradiated group (in FIG. 7, indicated withblack rhombuses);

(2) non-administered, radiotherapy-treated group (in FIG. 7, indicatedwith black circles);

(3) αSQAP C10:0-administered, un-irradiated group (in FIG. 7, indicatedwith white triangles); and

(4) αSQAP C10:0-administered, radiotherapy-treated group (in FIG. 7,indicated with white squares).

The drug was administered intraperitoneally from Day 1 to Day 5, 1 mg/kgonce a day. The subjects were exposed to radiation emitted from an X-raygenerator (HS-225, manufactured by Shimadzu Co., Ltd.) at a dose of 4 Gyon Day 1 and Day 4.

The results are shown in FIG. 7, indicating that the tumor volumeincreased with time in all the groups. However, the increase of thetumor volume was most suppressed in the (4) αSQAP C10:0-administered,radiotherapy-treated group in comparison with other groups.

Example V-6 Human Esophageal Squamous Cell Carcinoma

Human esophageal squamous cell carcinoma cells TE-8 were transplantedinto the right femoral region of KSN nude mice in a ratio of 1×10⁶ cellsper individual. After a tumor mass of about 50 mm³ was formed in eachindividual, four mice were assigned to each of the four groups (1) to(4):

(1) non-administered, un-irradiated group (in FIG. 8, indicated withblack rhombuses);

(2) non-administered, radiotherapy-treated group (in FIG. 8, indicatedwith black squares);

(3) αSQAP C18:0-administered, un-irradiated group (in FIG. 8, indicatedwith white squares); and

(4) αSQAP C18:0-administered, radiotherapy-treated group (in FIG. 8,indicated with white circles).

The drug was administered intraperitoneally from Day 1 to Day 5, 1 mg/kgonce a day. The subjects were exposed to radiation emitted from an X-raygenerator (HS-225, manufactured by Shimadzu Co., Ltd.) at a dose of 4 Gyon Day 1 and Day 4.

The results are shown in FIG. 8, indicating that the tumor volumeincreased with time in all the groups. However, the increase of thetumor volume was most suppressed in the (4) αSQAP C18:0-administered,radiotherapy-treated group in comparison with other groups.

Example VI Antineoplastic Effect Test

Human colonic adenocarcinoma cells SW480 were transplanted into theright femoral region of KSN nude mice in a ratio of 2×10⁶ cells perindividual. After a tumor mass of about 50 mm³ was formed in eachindividual, four mice were assigned to each of the two groups (1) and(2):

(1) non-administered (in FIG. 9, indicated with white squares); and

(2) ΔSQAP C18:0-administered (in FIG. 9, indicated with black squares).

The drug was administered intraperitoneally from Day 1 to Day 14, 20mg/kg once a day.

The results are shown in FIG. 9, indicating that the increase of thetumor volume was markedly suppressed in the αSQAP C18:0-administeredgroup in comparison with the non-administered group.

Example VII Tube Formation Inhibition Test Using Vascular EndothelialCell-Fibrocyte Cocultivation System

Using a angiogenesis kit (KZ-1000) manufactured by Kurabo IndustriesLtd., which is a cocultivation system for human vascular endothelialcells and human fibrocytes, the effects of αSQAP C10:0, αSQAP C14:0,αSQAP C18:0, αSQAP C22:0, βSQAP C18:0, and βQAP C18:1 on tube formationwere examined. Cultivation for tube formation using the kit wasconducted according to the manufacturer's instruction manual.

Using a medium containing a final concentration of 10 ng/ml of VEGF-Aand being designed specifically for angiogenesis, the respective SQAPcompounds were prepared to have intended concentrations. On Day 1 of thecell cultivation, special media each containing SQAP compounds at therespective concentrations and DMSO (negative control) were added to thecultivation systems. The systems were cultivated for 30 minutes, andirradiated with 2 Gy of cobalt 60. Thereafter, on Days 4, 7, and 10 ofthe cultivation, the media were replaced with newly prepared specialmedia containing SQAP or DMSO. The media were removed on Day 11 of thecultivation, fixed with 70% ethanol, and the formed tubes were stainedwith anti-human CD31 antibody. The stained figures were photographedunder an optical microscope, and the quantity of tube formation wascalculated by the image analysis. The angiogenesis index was calculatedaccording to the manufacturer's instruction manual.

The results are shown in FIG. 10. In comparison with the control groupnot treated with the SQAP compound and/or radiation therapy, the groupssubjected to radiation alone (2 Gy) and/or the SQAP compounds exhibitedlower angiogenesis indexes. In FIG. 10, “RT” is an abbreviation ofradiation therapy. Further, those treated with the SQAP compoundsexhibited lower indexes than the group treated with 2 Gy radiationalone. When combined with 2 Gy radiation, αSQAP C10:0 at finalconcentrations of 5, 10, and 20 μM, αSQAP C14:0 at final concentrationsof 5, 10, and 20 μM, αSQAP C18:0 at final concentrations of 5, 10, and20 μM, αSQAP C22:0 at final concentrations of 5, 10, and 20 μM, andβSQAP C18:0 at final concentrations of 5 and 10 μM, and βSQAP C18:1 atfinal concentrations of 5 and 10 μM inhibited tube formation in aconcentration-dependent manner.

Example VIII Toxicity Tests Example VIII-1 Ames Test

A reverse mutation assay (Ames test) was conducted using αSQAP C18:0.

Five strains composed of two strains of Salmonella typhimurium, whichare base pair substitution mutants, and one strain of Escherichia coli,and two strains of Salmonella typhimurium, which are frameshift mutantswere used as indicator bacterial strains. These strains wereprecultivated in the presence of αSQAP C18:0, and transferred to agarplates and cultivated thereon for 48 hours, and then the number ofrevertant colonies on the plate was counted. The amounts of αSQAP C18:0added to the respective plates were 2 μg, 7 μg, 21 μg, 62 μg, 185 μg,556 μg, 1667 μg, and 5000 μg. Regardless of the presence or absence ofS9 mix added during the precultivation (wherein S9 mix is a solutionprepared by adding cofactor-1 to a supernatant fraction of a liverhomogenate prepared from the liver of a male rat pretreated withphenobarbital and 5,6-benzoflavone), for all the strains, the number ofrevertant colonies did not increase. From this fact, mutagenicity of thesubstance was evaluated as negative.

Example VIII-2 Micronucleus Test

Micronucleus test was conducted by rat intravenous administration usingthe αSQAP C18:0 calcium salt.

Five male SD rats were assigned to each of the six groups (1) to (6):

(1) non-administered group;

(2) 25 mg/kg αSQAP C18:0-administered group;

(3) 50 mg/kg αSQAP C18:0-administered group;

(4) 100 mg/kg αSQAP C18:0-administered group;

(5) 200 mg/kg αSQAP C18:0-administered group; and

(6) positive control group (2 mg/kg mitomycin C-administered group).

The test solutions for (1) to (5) contained a normal saline solutioncontaining 10% CREMOPHOR EL as the solvents, and the above-describeddoses were administered to the rats twice in total for two consecutivedays. To the positive control group, the above-described dose wasadministered once.

About 24 hours after the administration, bone marrow smears wereprepared. Two thousands of immature erythrocytes were counted for eachindividual, and the incidence of immature erythrocytes having amicronucleus was calculated. As the index of marrow proliferationsuppression, the proportion of immature erythrocytes contained in 1000erythrocytes was calculated. The result indicates that no significantincrease was found in the incidence of micronuclei in the testsubstance-administered group in comparison with the non-administeredgroup. In addition, no influence was found on the marrow proliferationsuppression in the test substance-administered group. From these facts,the substance was evaluated as inducing no chromosomal aberration inbone marrow cells.

Example VIII-3 Single Dose Toxicity Test

Using αSQAP C18:0, an acute toxicity test was conducted on rats. Fivefemale and five male SD rats of 5 to 6 weeks old were assigned to eachof the groups (1) to (7):

(1) non-administered group;

(2) 25 mg/kg αSQAP C18:0-administered group;

(3) 50 mg/kg αSQAP C18:0-administered group;

(4) 100 mg/kg αSQAP C18:0-administered group;

(5) 200 mg/kg αSQAP C18:0-administered group;

(6) 400 mg/kg αSQAP C18:0-administered group; and

(7) 800 mg/kg αSQAP C18:0-administered group.

The test solution for (1) and (4) to (7) contained a normal salinesolution containing 10% CREMOPHOR EL, (2) contained a normal salinesolution containing 2.5% CREMOPHOR EL, and (3) contained a normal salinesolution containing 5% CREMOPHOR EL as the solvents.

These test solutions were administered via the rat tail vein at a rateof 0.13 ml/kg/minute, and the clinical signs were observed for two daysincluding the date of administration. No individual died during the testperiod, and the lethal dose was estimated to be higher than 800 mg/kg.

Other benefits and modifications would be readily understood by thoseskilled in the art. Accordingly, it is evident that the presentinvention in its broader aspect is not limited to the specific detailsand representative embodiments shown and described herein. Accordingly,various modifications may be made without departing from the spirit orscope of the general inventive concept as defined by the appended claimsand their equivalents.

The compound of the present invention is a novel substance, and, asdescribed above, has remarkable radiosensitizing effect andantineoplastic effect. The compound of the present invention isobtainable at high purity by a simple synthesis method. Further, thecompound of the present invention is structurally stable, and highlysoluble in water. Accordingly, the compound is advantageous in itsmanufacture and formulation when used as a drug, and is alsoadvantageous in the use after storage as a compound and a drug. Inaddition, the compound features low toxicity. Accordingly, the compoundis very advantageous as a drug to be administered to human and otheranimals over a short or long period.

The present invention is funded by Special Coordination Funds forPromoting Science and Technology provided by the Ministry of Education,Culture, Sports, Science and Technology.

Where a numerical limit or range is stated herein, the endpoints areincluded. Also, all values and subranges within a numerical limit orrange are specifically included as if explicitly written out.

Obviously, numerous modifications and variations of the presentinvention are possible in light of the above teachings. It is thereforeto be understood that, within the scope of the appended claims, theinvention may be practiced otherwise than as specifically describedherein.

All patents and other references mentioned above are incorporated infull herein by this reference, the same as if set forth at length.

1. A sulfoquinovosylacyl propanediol compound represented by formula(I):

wherein R₁ is an acyl residue of a fatty acid, Y is a number of 1, 2 or3, and M represents a cation having a positive charge equal to Y, orpharmaceutically acceptable salt thereof.
 2. An anion represented byformula (I′):

wherein R₁ is an acyl residue of a fatty acid.
 3. A pharmaceuticalcomposition, comprising at least one sulfoquinovosylacyl propanediolcompound or pharmaceutically acceptable salt thereof according to claim1 and a pharmaceutically acceptable carrier.
 4. A pharmaceuticalcomposition according to claim 3, which is a radiosensitizer.
 5. Thepharmaceutical composition according to claim 3, which is anantineoplastic or antitumor agent.
 6. The sulfoquinovosylacylpropanediol compound according to claim 1, wherein the acyl residue has26, or less and 1 or more carbon atoms.
 7. The sulfoquinovosylacylpropanediol compound according to claim 1, wherein the acyl residue has22 or less and 1 or more carbon atoms.
 8. The sulfoquinovosylacylpropanediol compound according to claim 1, wherein M is a hydrogen atom.9. The sulfoquinovosylacyl propanediol compound according to claim 1,wherein M is selected from the group consisting of sodium, potassium,calcium and magnesium.
 10. The sulfoquinovosylacyl propanediol compoundaccording to claim 1, wherein the compound is selected from the groupconsisting of3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-decanoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-decanoyl-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-myristoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-myristoyl-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-behenoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-behenoyl-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-hexanoyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-hexanoyl-propane-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-acetyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-acetyl-propane-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diolcalcium salt;3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-oleoyl-propane-1,3-diol sodiumsalt; and 3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-oleoyl-propane-1,3-diolcalcium salt.3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt. 3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolcalcium salt.
 11. A process for making a compound or pharmaceuticallyacceptable salt thereof according to claim 1, which comprises:deprotecting a compound of formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isan acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and Mrepresents a cation having a positive charge equal to Y, to obtain saidcompound or pharmaceutically acceptable salt thereof according toclaim
 1. 12. A process according to claim 11, wherein said compound offormula (IX) is prepared by a process comprising: oxidizing a compoundof formula (VIII):

wherein P¹, P², and P³ are each independently a protecting group, SAc isan acetylthio group, and R₁ is an acyl residue of a fatty acid, toobtain said compound of formula (IX).
 13. A process according to claim12, wherein said compound of formula (VIII) is prepared by a processcomprising: reacting a compound of formula (VII):

wherein P¹, P², and P³ are each independently a protecting group, andSAc is an acetylthio group, with a compound of formula R₁C(═O)L, whereinR₁ is an acyl residue of a fatty acid and L is a leaving group, toobtain said compound of formula (VIII).
 14. A process according to claim11, wherein said compound of formula (IX) is prepared by a processcomprising: reacting a compound of formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y, with a compound of formula R₁C(═O)L, wherein R₁ is an acylresidue of a fatty acid and L is a leaving group, to obtain saidcompound of formula (IX).
 15. A process according to claim 14, whereinsaid compound of formula (X′) is prepared by a process comprising:converting a compound of formula (IX′):

wherein P¹, P², and P³ are each independently a protecting group, and Tsis a tosyl group, to said compound of formula (X′).
 16. A compoundrepresented by formula (VIII):

wherein P¹, P², and P³ are each independently a protecting group, SAc isan acetylthio group, and R₁ is an acyl residue of a fatty acid.
 17. Acompound represented by formula (IX):

wherein P¹, P², and P³ are each independently a protecting group, R₁ isan acyl residue of a fatty acid, Y is a number of 1, 2 or 3, and Mrepresents a cation having a positive charge equal to Y.
 18. A compoundrepresented by formula (X′):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y.
 19. A compound represented by formula (IX′):

wherein P¹, P², and P³ are each independently a protecting group, and Tsis a tosyl group.
 20. A process for making a compound orpharmaceutically acceptable salt thereof according to claim 1, whichcomprises: reacting a compound of formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents a cation having apositive charge equal to Y, with a compound of formula R₁C(═O)L, whereinR₁ is an acyl residue of a fatty acid and L is a leaving group, toobtain said compound or pharmaceutically acceptable salt thereofaccording to claim
 1. 21. A process according to claim 20, wherein saidcompound of formula (IX″) is prepared by a process comprising:deprotecting a compound of formula (VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y, to obtain said compound of formula (IX″).
 22. A processaccording to claim 21, wherein said compound of formula (VIII″) isprepared by a process comprising: oxidizing a compound of formula (VII):

wherein P¹, P², and P³ are each independently a protecting group and SAcis an acetylthio group, to obtain said compound of formula (VIII″). 23.A compound represented by formula (VIII″):

wherein P¹, P², and P³ are each independently a protecting group, Y is anumber of 1, 2 or 3, and M represents a cation having a positive chargeequal to Y.
 24. A compound represented by formula (IX″):

wherein Y is a number of 1, 2 or 3, and M represents a cation having apositive charge equal to Y.
 25. A method of treating a tumor, comprisingadministering an effective amount of a compound according to claim 1 ora pharmaceutically acceptable salt thereof to a subject in need thereof.26. The method according to claim 25, wherein the compound is selectedfrom the group consisting of3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-decanoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-decanoyl-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-myristoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-myristoyl-1,3-diolcalcium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-behenoyl-1,3-diolsodium salt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-behenoyl-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-hexanoyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-hexanoyl-propane-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-acetyl-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-acetyl-propane-1,3-diolcalcium salt;3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diol sodiumsalt; 3-O-(6-sulfo-α-D-quinovopyranosyl)-1-O-formyloxy-propane-1,3-diolcalcium salt;3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-oleoyl-propane-1,3-diol sodiumsalt; and 3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-oleoyl-propane-1,3-diolcalcium salt.3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diol sodiumsalt. 3-O-(6-sulfo-β-D-quinovopyranosyl)-1-O-stearoyl-propane-1,3-diolcalcium salt.
 27. The method of claim 25, wherein said compound of claim1 or pharmaceutically acceptable salt thereof is administeredconcurrently with radiation therapy.
 28. The method of claim 25, whereinsaid compound of claim 1 or pharmaceutically acceptable salt thereof isadministered prior to radiation therapy.
 29. The method of claim 25,wherein said compound of claim 1 or pharmaceutically acceptable saltthereof is administered after radiation therapy.
 30. A method fortreating a malignant neoplasm comprising administering to a human inneed thereof an antineoplastic effective amount of at least one compoundaccording to claim
 1. 31. A method for treating a malignant neoplasmcomprising administering to a human in need thereof radiosensitizingamount of the compound according to claim 1 and exposing said human toan effective dose of radiation.